Curriculum Vitae - Harvard Medical School - Harvard University

1982 Outstanding Intern Award1981 Malamud Award - Best 4-year performance in psychiatry1981 CIBA-GEIGY Award - Best 4-year performance in neuroscience, neuroanatomy, and neurologyMEMBERSHIPS:1. Obsessive Compulsive Foundation, Co-Founder, First Chairman Scientific Advisory Board (SAB) (1986-1996) and Member, SAB (1996- )2. American College of Neuropsychopharmacology (ACNP), elected member 19923. Collegium Internationale Neuro-Psychopharmacologicum, elected member 19964. New York Psychiatric Society, elected member 20095. International Society for CNS Clinical Trials and Methodology (ISCTM), member 2009-6. Anxiety Disorders Association of America, Member7. Society of Biological Psychiatry, Member8. Advisory Board of the Council on Anxiety Disorders, Member9. American Medical Association10. Society for Neuroscience11. American Association for the Advancement of Science12. American Psychiatric Association, Member13. Florida Psychiatric Society, Member (1994-2007)14. Maryland Psychiatric Society, Member (2007-2009)15. Tourette’s Syndrome Association, MemberMEDICAL LICENSURE/SPECIALTY BOARDS:1. Diplomate, American Board of Psychiatry and Neurology #30620, 19882. Connecticut License #024505, 1983-19963. Florida Medical License #ME0074349, 10/22/97-present4. New York State Medical license #253258, 05/27/09 – 04/30/2011GOVERNANCE/SERVICEState or National1. Chair, FDA Psychopharmacologic Drug Advisory Committee (PDAC) (2004-2006); ad hoc member andacting chair (2006-2009)2. Member, Board of Directors, Florida Alzheimer’s Research Center, State of Florida, by gubernatorialappointment (Bush and Crist) (2004-2008).3. Member, Suicide Prevention Task Force (Bush) and Council (Crist), State of Florida, by gubernatorialappointment (2004 – present)4. Member, Child Development Commission, State of Florida, by gubernatorial appointment (Bush) Co-Chair,Steering Committee for Florida Psychopharmacology Algorithm (2002-2004)MSSM1. Member, Search Committee, Brain-Machine Interface2. Member, Quality and Patient Safety Council3. Member, Pediatrics Chair Search Committee4. Member, Speakers’ Bureau Committee5. Chair, Web Disclosure CommitteeNIMH/NIH1. NIMH: Member, Leadership Team2. NIH: Member, CTSA Steering Committee3. NIH: Member, CTSA Training & Education Workgroup4. NIMH: Member, Planning Committee, Research Track at APA meeting, 20085. NIMH: Member, NCDEU Steering Committee, 2008, 2009Updated 12/12/2009

University of Florida1. Search Committee Chair, UF McKnight Brain Institute Director2. Member, Executive Fiscal Affairs Committee, College of Medicine3. Secretary-Treasurer, Florida Clinical Practice Association, Inc.4. Member, Shands @ AGH Medical Staff Executive Committee5. Chair, Professorial Tenure and Promotions Committee, UF College of Medicine6. Member, Neurology Chair Search Committee7. Member, Deans Committee, Department of Veterans Affairs, Gainesville, FL8. Member, Board of Directors, Faculty Clinical Practice Association9. Member, Executive Committee of the Medical Staff, Gainesville, FL10. Member, Executive Committee, University Medical Center, Jacksonville, FL11. Behavioral Health Network Steering Committee12. Group Practice Operations Group13. Cost Management Steering Committee, Shands Hospital at UF14. Infection Control and Medical Services Committee, and member, AIDS subcommittee, Connecticut MentalHealth CenterTEACHING:MSSM1. Led monthly Chairman’s Journal Club for Psychiatry residentsUniversity of Florida2. Supervision and didactic instruction of University of Florida psychiatry residents3. Faculty, Human Behavior Course (1st year medical students) and Introduction to Clinical Psychiatry(rotating medical students)4. Supervision of Medical Student Research Projects5. Sponsor, ACNP Minority Mini-Fellowship6. Mentor on NARSAD and NIMH Career Development AwardsYale University1. Supervision of Yale psychiatric residents and medical students.2. Faculty, Neuropsychopharmacology, Psychopathology and Advanced Psychopharmacology courses3. Faculty, "Psychiatry 101," for 1 st year Medical Students, Seminar Group Leader.4. Lecturer in psychopharmacology for graduate psychology program5. Course Director, "Advanced Clinical Psychopharmacology" for PGY III psychiatry residents, ConnecticutMental Health CenterOTHER PROFESSIONAL ACTIVITIES:1. Standing Member, Interventions Review Committee, NIMH Study Section (until July 2007)2. External Reviewer, NIMH Intramural Program3. Member, Advocacy Committee, American College of Neuropsychopharmacology (ACNP)4. Member, Human Subjects Committee, ACNP5. Member, Membership Committee, American Psychiatric Association6. Reviewer: Archives of General Psychiatry; Molecular Psychiatry, Biological Psychiatry, AmericanJournal of Psychiatry, Psychosomatics; Journal of Clinical Psychiatry; The Medical Letter;Psychopharmacology; Psychological Reviews; New England Journal of Medicine; Journal of Neuropsychiatryand Clinical Neurosciences; Journal of Clinical Psychopharmacology; Depression andAnxiety; Behavior Therapy; Journal of Clinical Ethics7. Associate Editor, Mount Sinai Journal of Medicine8. Editorial Board: Psychosomatic Medicine9. External Reviewer, NIMH STAR*D Program10. Obsessive Compulsive Foundation, Chairman, Scientific Advisory Board 1986-9611. President, Southern Association for Research in Psychiatry, 2000-2001Updated 12/12/2009

12. Sponsor, NIMH Grant Writing Fellowship, 200213. Chair, Anxiety Disorders Association of America Annual Meeting, Miami, FL, March, 2004.14. Co-Director, 5 th Neurobiology of Disease in Children Symposium, Los Angeles, CA, September, 2005.BIBLIOGRAPHYOriginal Articles:1. Goodman WK, Charney DS: Biological approaches to the treatment of refractory depression. Yale Psych Quart,7(2):5-23, 1984.2. Goodman WK, Charney DS: Therapeutic applications and the mechanisms of action of monoamine oxidaseinhibitor and heterocyclic antidepressant drugs. J Clin Psychiatry, 46(10):6-22, 1985.3. Goodman WK, Charney DS, Price LH, Woods SW, Heninger GR: Ineffectiveness of clonidine in the treatment ofthe benzodiazepine withdrawal syndrome: Report of three cases. Am J Psychiatry, 143(7):900-903, 1986.4. Woods SW, Charney DS, Loke J, Goodman WK, Redmond DE, Jr., Heninger GR: Carbon dioxide sensitivity inpanic anxiety. Ventilatory and anxiogenic response to carbon dioxide in healthy subjects and patients with panicanxiety disorder before and after alprazolam treatment. Arch Gen Psych, 43:900-909, 1986.5. Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR: Drugtreatment of panic disorder: The comparative efficacy of imipramine, alprazolam and trazodone. J Clin Psychiatry,47:580-586, 1986.6. Price LH, Goodman WK, Charney DS, Rasmussen SA, Heninger GR: Treatment of severe obsessive-compulsivedisorder with fluvoxamine. Am J Psychiatry, 144(8):1059-1061, 1987.7. Charney DS, Woods SW, Goodman WK, Heninger GR: Serotonin function in anxiety: II. Effects of the serotoninagonist MCPP in panic disorder patients and healthy subjects. Psychopharm, 92:14-24, 1987.8. Charney DS, Woods SW, Goodman WK, Heninger GR: Neurobiological mechanisms of panic anxiety:Biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry, 144(8):1030-1036,1987.9. Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS: Effects of yohimbine in obsessivecompulsive disorder. Psychopharm, 93:308-313, 1987.10. Goodman WK, Charney DS: A case of alprazolam, but not lorazepam, inducing manic symptoms. J Clin Psychiatry,48(3):117-118, 1987.11. Woods SW, Charney DS, Goodman WK, Heninger GR: Carbon dioxide-induced anxiety: Behavioral, physiologic,and biochemical effects of C02 in patients with panic disorders and healthy subjects. Arch Gen Psych, 45:43-52,1988.12. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR: Serotonin function in obsessivecompulsivedisorder: A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients andhealthy subjects. Arch Gen Psych, 45:177-185, 1988.13. Leckman JF, Riddle MA, Berrettini WH, Anderson GM, Hardin M, Chappell P, Bissette G, Nemeroff CB,Goodman WK, Cohen DJ: Elevated CSF dynorphin A [1-8] in Tourette’s syndrome. Life Sci, 43:2015-2023, 1988.14. Goodman WK, Price LH, Charney DS: Fluvoxamine in obsessive compulsive disorder. Psychiatric Annals,19(2):92-96, 1989.15. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS: Efficacy of fluvoxamine inobsessive-compulsive disorder: A double-blind comparison with placebo. Arch Gen Psych, 46:36-44, 1989.16. Goodman WK, Price LH, Rasmussen SA, Heninger GR, Charney DS: Fluvoxamine as an antiobsessional agent.Psychopharmacol Bull, 25:31-36, 1989.17. Seibyl JS, Krystal JH, Goodman WK, Price LH: Obsessive-compulsive symptoms in a patient with a right frontallobe lesion: Response to lithium augmentation of tranyl-cypromine. Neuropsychiatry, Neuropsych, & BehavNeurology, 1(4):295-299, 1989.18. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: TheYale-Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use, and reliability. Arch Gen Psych,46:1006-1011, 1989. *Over 1,600 citations as of 5/2006.19. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-BrownObsessive Compulsive Scale (Y-BOCS): Part II. Validity. Arch Gen Psych, 46:1012-1016, 1989.20. McDougle CJ, Goodman WK, Delgado PL, Price LH: Pathophysiology of obsessive-compulsive disorder. Am JUpdated 12/12/2009

Psychiatry, 146(10):1350-1, 1989.21. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR: Neuroleptic additionin fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry, 147(5):652-654, 1990.22. McDougle CJ, Price LH, Goodman WK: Fluvoxamine treatment of coincident autistic disorder and obsessivecompulsivedisorder: A Case Report. J Autism & Devel Disorders, 20(4):537-543, 1990.23. Delgado P, Goodman W, Price L, Heninger G, Charney D: Fluvoxamine/pimozide treatment of concurrentTourette’s and OCD. Brit J Psych, 157:762-765, 1990.24. Leckman JF, Goodman WK, Riddle MA, Hardin MT, Anderson GT: Low CSF 5HIAA and obsessions of violence:Report of two cases. Psychiatry Research, 33: 95-99, 1990.25. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, CharneyDS: Specificity of serotonin reuptake inhibitors in the treatment of obsessive- compulsive disorder: Comparison offluvoxamine and desipramine. Arch Gen Psych, 47:577-585, 1990.26. DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen SA: Clinical predictors of treatment response inobsessive compulsive disorder: Exploratory analyses from a multicenter trials of clomipramine. PsychopharmacolBull, 26(1):54-59, 1990.27. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF: Beyond the serotonin hypothesis: Arole for dopamine in some forms of obsessive compulsive disorder? J Clin Psych, 51(8):36-43 (Suppl.), 1990.28. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR: Clinical studies of 5-HT function using I.V. L-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry, 14 (4):459-472, 1990.29. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR: Clinical data on the roleof serotonin in the mechanism(s) of action of antidepressant drugs. J Clin Psych, 51:44-50 (Suppl.), 1990.30. Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA: Results ofa double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessivecompulsivedisorder. Psychopharmacol Bull, 26(3):279-284, 1990.31. Goodman W, McDougle C, Price L, Riddle M, Smith E, Hoffer P, Woods S: SPECT imaging of obsessivecompulsivedisorder with Tc-99m d,l-HMPAO. J Nucl Med, 31:750, 1990.32. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR: A controlled trial of lithium augmentation influvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy. J Clin Psychopharm, 11(3):175-184, 1991.33. Wexler BE, Goodman WK: Cerebral laterality, perception of emotion and treatment response in obsessivecompulsivedisorder. Biol Psych, 29:900-908, 1991.34. DeVeaugh-Geiss J, Katz R, Landau P, Akiskal H, Ananth J, Ballenger J, Betts WC, Diamond B, Feiger A, Foa E,Fogelson D, Goodman W, Greist J, Himmelhoch J, Hoehn-Saric R, Jenike M, Kim SW, Liebowitz M,Mavissakalian M, Ninan P, Noyes R, Rasmussen S, Ringold A, Shear K: Clomipramine in the treatment of patientswith obsessive-compulsive disorder. Arch Gen Psych, 48:730-738, 1991.35. Boyarsky BK, Perone LA, Lee NC, Goodman WK: Current treatment approaches to obsessive-compulsive disorder.Arch Psychiatr Nurse, 5(5):299-306, 1991.36. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ:Clomipramine in autism: Preliminary evidence of efficacy. J. Am. Acad Child Adolesc Psych, 31(4):746-750, 1992.37. Riddle MA, Rasmusson A, Woods S, Hoffer P, Hardin M, Smith E, Goodman WK, Smith JC, Herbst D, Scahill L,Ort S, Rattner Z, Zubal I, Cohen DJ, Leckman JF: SPECT Imaging of regional cerebral blood flow in Tourette'ssyndrome. Adv Neurol, 58:207-211, 1992.38. King RA, Riddle MA, Goodman WK: Psychopharmacology of obsessive-compulsive disorder in Tourettesyndrome. Adv Neurol, 58:283-91, 1992.39. Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS: The serotonin hypothesis of obsessive compulsivedisorder: implications of pharmacologic challenge studies. J Clin Psychiatry, 53:17-28 (Suppl.), 1992.40. Goodman WK, McDougle CJ, Price LH: Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry,53:29-37 (Suppl.), 1992.41. Goodman WK, McDougle CJ, Price LH: The role of serotonin and dopamine in the pathophysiology of OCD. IntClin Psychopharmacol, 7:35-38 (Suppl 1), 1992.42. Barr LC, Goodman WK, Price LH: Acute exacerbation of body dysmorphic disorder during tryptophan depletion.Am J Psychiatry, 149(10):1406-7, 1992.43. Goodman WK, Price LH: Assessment of severity and change in obsessive compulsive disorder. Psychiatr ClinNorth Am, 15(4):861-9, 1992.44. McDougle C, Goodman W, Leckman J, Holzer J, Barr L, McCance-Katz E, Heninger G, Price L: Limited therapeuticUpdated 12/12/2009

effect of addition of buspirone in fluvoxamine-refractory obsessive- compulsive disorder. Am J Psychiatry, 150:647-649, 1993.45. Rotter M, Goodman W: The relationship between insight and control in obsessive-compulsive disorder:Implications for the insanity defense. Bull Am Acad Psych Law, 21(2):245-252, 1993.46. McDougle C, Naylor S, Goodman WK, Volkmar FR, Cohen DJ, Price LH: Acute tryptophan depletion in autisticdisorder: A controlled case study. Biol Psych, 33:547-550, 1993.47. Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR: Effects of the serotoninreuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psych Research, 48:119-133, 1993.48. Calvocoressi L, McDougle CI, Wasylink S, Goodman WK, Trufan SJ, Price LH: Inpatient treatment of patientswith severe obsessive-compulsive disorder. Hosp Comm Psych, 44(12):1150-1154, 1993.49. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH: The efficacy of fluvoxamine inobsessive-compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharmacol, 13(5):354-358,1993.50. McDougle CJ, Goodman WK, Price LH: The pharmacotherapy of obsessive-compulsive disorder.Pharmacopsychiatry, 26:24-29(suppl 1), 1993.51. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH: Biological approaches to treatment-resistantobsessive compulsive disorder. J Clin Psych, 54:16-26(suppl), 1993.52. Barr LC, Goodman WK, Price LH: The serotonin hypothesis of obsessive compulsive disorder. Int ClinPsychopharmacol, 8:79-82(suppl 2), 1993.53. McDougle CJ, Goodman WK, Leckman JF, Price LH: The psychopharmacology of obsessive compulsivedisorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am, 16(4):749-66, 1993.54. McDougle C, Goodman W, Price L: Dopamine antagonists in tic-related and psychotic spectrum obsessivecompulsive disorder. J Clin Psych, 55:24-31(suppl 3), 1994.55. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH: Haloperidol addition in fluvoxaminerefractoryobsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and withouttics. Arch Gen Psych, 51:302-308, 1994.56. Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, Price LH: Tryptophan depletionin patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psych,51:309-317, 1994.57. Holzer JC, Goodman WK, McDougle CJ, Baer L, Boyarsky BK, Leckman JF, Price LH: Obsessive-compulsivedisorder with and without a chronic tic disorder: A comparison of symptoms in 70 patients. Brit J Psych, 164:469-473, 1994.58. Tollefson GD, Rampey AH Jr., Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear MK, GoodmanW, Genduso LA: A multicenter investigation of fixed-dose fluoxetine in the treatment of OCD. Arch Gen Psych,51:559-567, 1994.59. Leckman J, Walker D, Goodman W, Pauls D, Cohen D: "Just Right" perceptions associated with compulsivebehavior in Tourette's syndrome. Am J Psychiatry, 151(5):675-680, 1994.60. Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, Anderson GM, Riddle MA,McSwiggan-Hardin M, McDougle CJ, Barr LC, Cohen DJ: Elevated cerebrospinal fluid levels of oxytocin inobsessive-compulsive disorder: Comparison with Tourette’s syndrome and healthy controls. Arch Gen Psych,51:782-792, 1994.61. Leckman JF, Goodman WK, North WG, Chappell, PB, Price LH, Pauls DL, Anderson GM, Riddle MA, McDougleCJ, Barr LC, Cohen DJ: The role of central oxytocin in OCD and related normal behavior. Psychoneuroendocrin;19(8):723-749, 1994.62. Goddard AW, Sholomskas DE, Walton KE, Augeri FM, Charney DS, Heninger GR. Goodman WK, Price LH:Effects of tryptophan depletion in panic disorder. Biol Psych, 36:775-777, 1994.63. Barr LC, Goodman WK, Price LH: Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry151(2):289, 1994.64. Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ,Scahill L, Ort SI, Pauls DL, Cohen DJ, Price LH: Cerebrospinal fluid biogenic amines in obsessive compulsivedisorder, Tourette’s syndrome and healthy controls. Neuropsychopharmacology, 12:73-86, 1995.65. McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, Price LH: A case-controlled studyof repetitive thoughts and behaviors in adults with autistic disorder and obsessive- compulsive disorder. Am JPsychiatry, 152(5):772-777, 1995.Updated 12/12/2009

66. Calvocoressi L, Lewis B, Harris M, Trufan S, Goodman W, McDougle C, Price L: Family accommodation inobsessive-compulsive disorder. Am J Psychiatry, 152(3):441-443, 1995.67. Pauls DL, Alsobrook JP, Goodman W, Rasmussen S, Leckman JF: A family study of obsessive compulsivedisorder. Am J Psychiatry, 152(1):76-84, 1995.68. Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike MA, Rasmussen SA: DSM-IV field trial: Obsessivecompulsivedisorder. Am J Psychiatry, 152(1):90-96, 1995.69. Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik F, Charney DS, Heninger GR: m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation. BiolPsychiatry, 38:138-149, 1995.70. Barr LC, Goodman WK, Delgado PL, McDougle CJ, Price LH: Tryptophan depletion does not alter symptomseverity in drug-free obsessive compulsive disorder patients. Biol Psychiatry, 39:74-85, 1995.71. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH: Lack of efficacy of clozapinemonotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry, 152(12):1812-1814, 1995.72. Leckman JF, Grice DE, Barr LC, de Vries AL, Martin C, Cohen DJ, McDougle CJ, Goodman WK, Rasmussen SA:Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety, 1(5):208-215, 1994-95.73. Goddard AW, Charney DS, Germine M, Woods SW, Heninger GR, Krystal JH, Goodman WK, Price LH: Effectsof tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry, 38:74-85,1995.Goodman WK, Kozak MJ, Liebowitz M, White KL: Treatment of obsessive-compulsive disorder withfluvoxamine: a multicenter, double-blind, placebo-controlled trial. Int Clin Psychopharmacol, 11(1):21-29, 1996.74. Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, CohenD: Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette’s syndrome: Comparison to OCD and normalcontrols. Biol Psych, 39(9):776-783, 1996.75. Jenike MA, Rauch SL, Cummings JL, Savage CR, Goodman WK: Recent developments in neurobiology ofobsessive-compulsive disorder. J Clin Psychiatry, 57(10):492-503, 1996.76. Byerly MJ, Goodman WK, Christensen R: High doses of sertraline for treatment-resistant obsessive-compulsivedisorder. Am J Psychiatry, 153(9):1232-1233, 1996.77. Barr L, Heninger G, Goodman W, Charney D, Price L: Effects of fluoxetine administration on mood response totryptophan depletion in healthy subjects. Biol Psych, 41:949-954, 1997.78. Murphy T, Goodman W, Fudge M, Williams R, Ayoub E, Dalal M, Lewis M, Zabriskie J: B Lymphocyte AntigenD8/17: A peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette’s syndrome? Am JPsychiatry, 154(3):402-407, 1997.79. Barr LK, Goodman WK, Anand A, McDougle CJ, Price LH: Addition of desipramine to serotonin reuptakeinhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry, 154(9):1293-1295, 1997.80. Rasmusson AM, Anderson GM, Lynch KA, McSwiggan-Hardin M, Scahill LD, Mazure CM, Goodman WK, PriceLH, Cohen DJ, Leckman JF: A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms,and mood in Tourette’s syndrome. Biol Psychiatry, 41:117-121, 1997.81. Scahill L, Riddle MA, McSwiggan-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF:Children's Yale-Brown obsessive compulsive scale: Reliability and validity. Am J Child Adol Psychiatry,36(6):844-852, 1997.82. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman, WK: A severity rating scale forBody Dysmorphic Disorder: Development, reliability, and validity of a modified version of the Yale-Brownobsessive compulsive scale. Psychopharmacol Bull, 33(1):17-22, 1997.83. Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, Alsobrook J, Peterson BS, Cohen DJ, RasmussenSA, Goodman WK, McDougle CJ, Pauls DL: Symptoms of obsessive-compulsive disorder, Am J Psychiatry,154(7):911-917, 1997.84. Morris MR, Blashfield RK, Rankupalli B, Bradley MM, Goodman WK: Subclinical OCD in college students.Depression and Anxiety, 4:233-236, 199785. McDougle, CJ, Goodman WK: Combination pharmacological treatment strategies. Med Psychiatry, 6:203-223,1997.86. Eisen JL, Goodman WK, Keller MB, Warshaw MG, DeMarco LM, Luce DD, Rasmussen SA: Patterns of remissionand relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry, 60(5):346-345, 1999.87. Triggs W, McCoy K, Greer R, Rossi F, Bowers D, Kortenkamp S, Nadeau S, Heilman K, Goodman W: Effects ofleft frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. BiolPsychiatry, 45(11):1440-1446, 1999.Updated 12/12/2009

88. Alsobrook J, Leckman JF, Goodman WK, Rasmussen SA, Pauls DL: Segregation analysis of OCD using symptombasedfactor scores. Am J Med Genet, 88(6):669-675, 1999.89. Murphy TK, Goodman WK, Ayoub EM, Voeller KK: On defining Sydenham's chorea: Where do we draw the line?Biol Psychiatry, 47(10):851-857, 2000.90. Stein DJ, Goodman WK, Rauch SL: The cognitive-affective neuroscience of obsessive-compulsive disorder.Current Psychiatry Reports, 2(4):341-346, 2000.91. Morris MR, Forbes S, Bradley MM, Goodman WK: Stability of subclinical obsessive compulsive disorder incollege students, Depression and Anxiety, 11(4):180-182, 2000.92. Romano S, Goodman W, Tamura R., Gonzales J, and Collaborative Research Group: Long-term treatment ofobsessive compulsive disorder following acute response: A comparison of fluoxetine versus placebo. J ClinPsychopharmacol, 21(1):46-52, 2001.93. Stein DJ, Liu Y, Shapira NA, Goodman WK: The psychobiology of obsessive-compulsive disorder: How importantis the role of disgust? Current Psych Reports, 3(4):281-287, 2001.94. Murphy TK, Benson N, Zaytoun A, Yang M, Braylan R, Ayoub E, Goodman WK: Progress Toward analysis ofD8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder. JNeuroimmunology, 120(1-2):146-151, 2001.95. Murphy TK, Goodman WK: Genetics of childhood disorders: XXXIV. Autoimmune disorders, part 7: D8/17reactivity as an immunologic marker of susceptibility to neuropsychiatric disorders? J Am Acad Child AdolescPsychiatry, 41(1):98-100, 2002.96. Mataix-Cols D, Rauch SL, Baer L, Eisen, JL, Shera DM, Goodman W, Rasmussen A, Jenike MA: Symptomstability in adult obsessive compulsive disorder: Data from a naturalistic two-year follow-up study; Am JPsychiatry, 159(2):263-268, 2002.97. Shapira N, Lessig M, Murphy T, Driscoll D, Goodman W: Topiramate attenuates self-injurious behavior in Prader-Willi syndrome. Intern J Neuropsychopharm, 5(2):141-5, 2002.98. Nadeau SE, McCoy KJ, Crucian GP, Greer RA, Rossi F, Bowers D, Goodman WK, Heilman KM, Triggs WJ.Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation:evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol, 15(3):159-75, 2002.99. Ward HE, Shapira NA, Goodman WK. Non-pharmacologic somatic treatments of anxiety disorders. PrimaryPsychiatry, 9:55-58, 2002.100. Hollander E, Koran L, Goodman W, Greist J, Ninan P, Yang H, Li D, Barbato L: A double-blind, placebocontrolledstudy of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsivedisorder. J Clin Psychiatry, 64(6):640-647, 2003.101. Lieberman J, Tollefson G, Tohen M, Green A, Gur R, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H,Hamer R, HGDH Study Group: Comparative efficacy and safety of atypical and conventional antipsychotic drugs infirst-episode psychosis: a randomized double-blind trial of olanzapine vs. haloperidol. Am J Psychiatry, 160(8):1396-1404, 2003.102. Shapira NA, Liu Y, He AG, Bradley MM, Lessig MC, James GA, Stein DJ, Lang PJ, Goodman WK: Brainactivation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry, 54:751-756, 2003.103. Storch EA, Gelfand KM, Geffken GR, Goodman WK. An intensive outpatient approach to the treatment ofobsessive-compulsive disorder: Case exemplars. Annals of the American Psychotherapy Association, Winter:14-19,2003.104. Murphy TK, Sajid M, Soto O, Shapira N, Edge PJ, Yang M, Lewis M, Goodman WK. Detecting pediatricautoimmune neuropsychiatric disorders associated with strepto-coccus (PANDAS) in children with OCD and tics.Biol Psychiatry, 55:61-68, 2004105. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK: A double-blind placebocontrolled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry,55(5):553-5, 2004.106. Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ. Effects of topiramate in adults with Prader-WilliSyndrome. Am J Ment Retard, 109(4):301-9, 2004.107. Storch EA, Murphy TK, Geffken G, Soto O, Sajid M, Allen P, Roberti J, Killiany E, Goodman W. PsychometricEvaluation of the Children’s Yale-Brown Obsessive Compulsive Scale. Psych Research, 129, 91-98, 2004.108. Storch EA, Murphy TK, Geffken G, Soto O, Sajid M, Allen P, Roberti J, Killiany E, Goodman W. FurtherPsychometric Properties of the Tourette’s Disorder Scale – Parent Rated Version (TODS-PR). Child Psychiatry HumDev, 35(2):107-20, 2004.Updated 12/12/2009

109. Geffken GR, Storch EA, Gelfand KM, Adkins JK, Goodman W. Cognitive-behavioral psychotherapy for obsessivecompulsivedisorder: A review of treatment techniques. J Psychosocial Nurs, 42(12):44-51, 2004.110. Wright P, He AG, Shapira NA, Goodman WK, Liu Y. Disgust and the insula: fMRI responses to pictures ofmutilation and contamination. NeuroReport, 15(15):2347-2351, 2004.111. Okun MS, Bowers D, Springer U, Shapira NA, Malone D, Rezai AR, Nuttin B, Heilman KM, Morecraft RJ,Rasmussen SA, Greenberg BD, Foote KD, Goodman WK: What’s in a “Smile?” Intra-operative Observations ofContralateral Smiles Induced by Deep Brain Stimulation. Neurocase, 10(4):271–279, 2004.112. Storch EA, Murphy TK, Geffken GR, Soto O, Sajid M, Bagner DM, Allen P, Killiany EM, Goodman WK. Factoranalytic study of the Children’s Yale-Brown Obsessive-Compulsive Scale. J Clin Child & Adol Psych, 34:312-319,2005.113. Byerly M, Goodman W, Acholonu W, Bugno R, Rush AJ. Obsessive compulsive symptoms in schizophrenia:Frequency and clinical features. Schizophr Research, 15;76(2-3):309-16, 2005.114. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: Pooled results fromdouble-blind, placebo-controlled articles. J Affective Disorders, 87(2-3):161-7, 2005.115. Stein D, Andersen H, Goodman W. Escitalopram for the treatment of GAD: efficacy across different subgroups andoutcomes. Ann Clin Psychiatry, 17(2):71-5, 2005.116. Geffken GR, Storch EA, Duke D, Lewin A, Monaco L, Goodman WK. Hope and coping in family members ofpatients with obsessive compulsive disorder. J Anxiety Disorders, 20:614-629, 2006.117. Storch E, Shapira N, Dimoulas E, Geffken G, Goodman W. Yale-Brown Obsessive Compulsive Scale: The dimensionalstructure revisited. Depression and Anxiety, 22:28-35, 2005.118. Storch EA, Murphy TK, Geffken GR, Sajid M, Allen P, Roberti JW, Goodman WK. Reliability and validity of theYale Global Tic Severity Scale. Psychological Assessment, 17(4):486-491, 2005.119. Shapira NA, Okun MS, Wint DP, Foote KD, Byars JA, Bowers D, Springer U, Lang P, Greenberg BD, Haber SN,Goodman WK. Panic and fear induced by deep brain stimulation. J Neurol Neurosurg Psychiatry, 77(3):410-412,2006.120. Springer U, Bowers D, Goodman W, Shapira N, Foote K, Okun M. Long-term Habituation of the Smile Responsewith Deep Brain Stimulation. Neurocase, 12(3):191-6, 2006.121. Hirsh A, O’Brien K, Geffken G, Adkins J, Goodman W K, Storch EA. Intensive cognitive-behavior therapy for anelderly patient with obsessive-compulsive disorder and comorbid medical conditions. Amer J Geriatric Psych,14(4):380-1, 2006.122. Storch EA, Murphy TK, Bagner DM, Johns N, Baumeister A, Goodman WK, Geffken GR. Reliability and Validityof the Child Behavior Checklist Obsessive-Compulsive Scale. J Anxiety Disorders, 20(4):473-85, 2006.123. Storch EA, Larson M, Shapira NA, Ward HE, Murphy TK, Geffken GR, Valerio H, Goodman WK. Clinicalpredictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety,23(7):429-33,2006.124. Olson LL, Singer HS, Goodman WK, Maria BL. Tourette syndrome: diagnosis, strategies, therapies, pathogenesis,and future research directions. J Child Neurol, 21(8):630-41, 2006.125. Storch EA, Ledley DR, Lewin AB, Murphy TK, Johns NB, Goodman WK, Geffken GR. Peer victimization inchildren with obsessive-compulsive disorder: relations with symptoms of psychopathology. J Clin Child AdolescPsychol, 35(3):446-55, 2006.126. Storch EA, Murphy TK, Lewin AB, Geffken GR, Johns N, Jann KE, Goodman WK. The Children’s Yale-BrownObsessive Compulsive Scale: Psychometric Properties of Child- and Parent-Report Formats. J Anxiety Disorders,20(8):1055-1070, 2006.127. Goodman WK, Storch EA, Geffken GR, Murphy TK. Obsessive-compulsive Disorder In Tourette Syndrome. JChild Neurol, 21(8):704-14, 2006.128. Storch EA, Murphy TK, Geffken GR, Mann G, Adkins J, Merlo LJ, Duke D, Munson M, Swaine Z, Goodman WK.Cognitive-Behavioral Therapy for PANDAS Related Obsessive-Compulsive Disorder: Findings from a PreliminaryWait-List Controlled Open Trial. J Amer Acad of Child Adoles Psychiatry, 45(10):1171-1178, 2006.129. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK,Rasmussen SA. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder.Neuropsychopharm, 31(11):2394, 2006. Erratum in: Neuropsychopharm, 31(11):2394, 2006.130. Storch EA, Murphy TK, Fernandez M, Krishnan M, Geffken GR, Kellgren AR, Goodman WK. Factor analytic studyof the Yale Global Tic Severity Scale. Psychiatry Res. 149(1-3):231-7, 2007.131. Murphy TK, Snider LA, Mutch PJ, Harden E, Zaytoun A, Edge PJ, Storch EA, Yang MCK, Mann G, GoodmanUpdated 12/12/2009

WK, Swedo SE. Relationship of Movements and Behaviors to Group A Streptococcus Infections in ElementarySchool Children. Biol Psychiatry, 61(3):279-84, 2007.132. Okun MS, Mann G, Foote KD, Shapira NA, Bowers D, Springer U, Knight W, Martin P, Goodman WK. InternalCapsule and Nucleus Accumbens Region DBS: Responses Observed During Active and Sham Programming. JNeurol Neurosurg Psychiatry, 78(3):310-4, 2007.133. Husted D, Shapira N, Murphy TK, Mann GD, Ward HE, Goodman WK. Effect of Comorbid Tics on a ClinicallyMeaningful Response to 8-Week Open-label Trial of Fluoxetine in Obsessive Compulsive Disorder. J PsychiatricResearch, 41(3-4): 332-7, 2007.134. Storch EA, Stigge-Kaufman D, Marien W, Sajid M, Jacob ML, Geffken GR, Goodman WK, Murphy TK. Obsessive-Compulsive Disorder in Youth with and without a Chronic Tic Disorder. Depression and Anxiety, 2007 Mar 7; [Epubahead of print].135. Storch EA, Geffken GR, Merlo LJ, Mann G, Duke D, Munson M, Adkins J, Grabill K, Murphy TK, Goodman WK.Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensiveand weekly approaches. J Amer Acad Child Adoles Psychiatry, 46(4):469-478, 2007.136. Storch EA, Merlo LJ, Larson MJ, Fernandez M, Jacob ML, Geffken GR, Grabill K, Murphy TK, Goodman WK.Family Accommodation in Pediatric Obsessive-Compulsive Disorder. J Amer Acad Child Adoles Psychiatry,36(2):207-216, 2007.137. Storch EA, Merlo LJ, Lack C, Milsom V, Geffken GR, Goodman WK, Murphy TK. Quality of Life in Youth withTourette’s Syndrome and Chronic Tic Disorder. J Clin Child Adoles Psychology, Jun 36(2):217-227, 2007.138. Storch EA, Bagner DM, Geffken GR, Adkins JW, Murphy TK, Goodman WK. Sequential cognitive-behavioraltherapy for children with obsessive-compulsive disorder with an inadequate medication response: a case series offive patients. Depress Anxiety, 24(6):375-81, 2007.139. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, FernandezM, Geffken GR, Goodman WK. D-Cycloserine Does Not Enhance Exposure-Response Prevention Therapy inObsessive-Compulsive Disorder. Internat’l J Clin Psychopharm, 22:230-237, 2007.140. Storch EA, Merlo LJ, Lehmkuhl H, Grabill KM, Geffken GR, Goodman WK, Murphy TK. Further PsychometricExamination of the Tourette's Disorder Scales. Child Psychiatry Hum Dev. 38(2):89-98, 2007.141. Storch EA, Lack CW, Simons LE, Goodman WK, Murphy TK, Geffken GR. A Measure of Functional Impairmentin Youth with Tourette's Syndrome. J Pediatr Psychol, 32(8):950-9, 2007.142. Storch EA, Lack CW, Merlo LJ, Geffken GR, Jacob MJ, Murphy TK, Goodman WK. Clinical features of childrenand adolescents with obsessive-compulsive disorder and hoarding symptoms. Comprehensive Psychiatry,48(4):313-8, 2007.143. Storch EA, Lack C, Merlo LJ, Marien W, Geffken GR, Grabill K, Jacob ML, Murphy TK, Goodman WK.Associations between miscellaneous symptoms and symptom dimensions: An examination of pediatric obsessivecompulsivedisorder. Behav Res Ther, 45: 2593-2603, 2007.144. Storch EA, Kaufman D, Bagner D, Merlo LJ, Shapira NA, Geffken GR, Murphy TK, Goodman WK. FloridaObsessive-Compulsive Inventory: Development, reliability, and validity. J Clinical Psychology, 63(9):851-859,2007.145. Storch EA, Murphy TK, Lack CW, Geffken GR, Jacob ML, Goodman WK. Sleep-related problems in pediatricobsessive-compulsive disorder. J Anxiety Disorders, 2007 Sep 16; [2008].146. Storch EA, Merlo LJ, Larson MJ, Bloss CS, Geffken GR, Jacob ML, Murphy TK, Goodman WK. Symptomdimensions and cognitive-behavioural therapy outcome for pediatric obsessive-compulsive disorder. Acta PsychiatrScand, 117(1):67-75, 2008.147. Storch EA, Merlo LJ, Larson M, Marien WE, Geffken GR, Jacob ML, Goodman WK, Murphy TK. Clinical featuresassociated with treatment resistant pediatric Obsessive-Compulsive Disorder. Comprehensive Psychiatry, 49(1):35-42, 2008.148. Storch EA, Larson MJ, Merlo LJ, Keeley M, Jacob ML, Geffken GR, Murphy TK, Goodman WK. Comorbidity ofpediatric obsessive-compulsive disorder and anxiety disorders: impact on symptom severity, emotional functioning,and impairment. J Psychopath and Behav Assessment, (2008 XX).149. Storch EA, Milsom VA, Merlo LJ, Larson M, Geffken GR, Jacob ML, Murphy TK, Goodman WK. Insight inPediatric Obsessive-Compulsive Disorder: Associations with Clinical Presentation. Psychiatry Research,160(2):212-20, 2008.Updated 12/12/2009

150. Storch EA, Merlo LJ, Larson M, Geffken GR, Lehmkuhl HD, Jacob ML, Murphy TK, Goodman WK. Impact ofComorbidity on Cognitive-Behavioral Therapy Response in Pediatric Obsessive Compulsive Disorder. J AmerAcad Child Adol Psychiatry, 47(5):583-92, 2008.151. Goldstein RB, Storch EA, Lehmkuhl H, Geffken GR, Goodman WK, Murphy TK. Successful Medication Withdrawalafter Cognitive-Behavioral Therapy in a Treatment Resistant Pre-adolescent Male with Obsessive-CompulsiveDisorder. Depression and Anxiety, 26(1):E23-5, 2009.152. Storch EA, Merlo LJ, Lehmkuhl H, Geffken GR, Jacob M, Ricketts E, Murphy TK, Goodman WK. Cognitivebehavioraltherapy for obsessive-compulsive disorder: Comparison of intensive and weekly approaches. J AnxietyDisorders, (2008).153. Storch EA, McNamara J, Jordan C, Marien WE, Jacob M, Murphy TK, Goodman WK, Geffken GR. Associationsbetween Miscellaneous Symptoms and Symptom Dimensions in Adults with Obsessive-Compulsive Disorder.Anxiety, Stress, and Coping, 21(2):199-212, 2008.154. Storch EA, Merlo LJ, Keeley ML, Grabill K, Milsom V, Geffken G, Ricketts E, Murphy TK, Goodman WK.Somatic Symptoms in Children and Adolescents with Obsessive-Compulsive Disorder: Associations with ClinicalCharacteristics and Cognitive-Behavioral Therapy Response. Behavioural and Cognitive Psychotherapy, (in pressXX).155. Okun MS, Fernandez HH, Foote KD, Murphy T, Goodman WK. Avoiding Deep Brain Stimulation Failures inTourette Syndrome. J. Neurol.Neurosurg.Psychiatry, 79:111-112, 2008156. Aldea, MA, Geffken GR, Jacob ML, Goodman WK, Storch EA. Further psychometric analysis of the FloridaObsessive-Compulsive Inventory. J Anxiety Disorder, 23(1):124-9, 2009.157. Stewart SE, Rosario MC, Baer L, Carter AS, Brown TA, Scharf JM, Illmann C, Leckman JF, Sukhodolsky D,Katsovich L, Rasmussen S, Goodman W, Delorme R, Leboyer M, Chabane N, Jenike MA, Geller DA, PaulsDL.Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults. JAmerican Academy Child Adolescent Psychiatry. 2008;47(7):763-72.158. Storch EA, Abramowitz J, Goodman WK. Where does obsessive-compulsive disorder belong in DSM-V? DepressAnxiety.25(4):336-47;2008.159. Gallant J, Storch EA, Merlo LJ, Ricketts ED, Geffken GR, Goodman WK, Murphy TK. Convergent anddiscriminant validity of the Children's Yale-Brown Obsessive Compulsive Scale-Symptom Checklist.J AnxietyDisorder. 2008 22:1146-58160. Sulkowski ML, Storch EA, Geffken GR, Ricketts E, Murphy TK, Goodman WK. Concurrent validity of the Yale-Brown Obsessive-Compulsive Scale-Symptom Checklist. J Clin Psychol. 2008 Dec;64(12):1338-51161. Greenberg BD, Gabriels LA, Malone DA, Rezai AR, Friehs GM, Okun MS, Shapira NA, Foote KD, Cosyns PR,Kubu CS, Malloy PF, Salloway SP, Giftakis JE, Rise MT, Machado AG, Baker KB, Styulkowski PH, GoodmanWK, Rasmussen SA, Nuttin BJ. Deep brain stimulation of the ventral internal capsule/ventral striatum forobsessive-compulsive disorder: worldwide experience. Mol Psychiatry, May 20 th advance online publication:1-16,2008.162. Brady LS, Winsky L, Goodman W, Oliveri ME, Stover E. NIMH Initiatives to Facilitate Collaborations AmongIndustry, Academia, and Government for the Discovery and Clinical Testing of Novel Models and Drugs forPsychiatric Disorders. Neuropsychopharmacology. 2009 34:229-43.163. Wang PS, Heinssen R, Oliveri M, Wagner A, Goodman W. Bridging the Bench and Practice:Translational Researchfor Schizophrenia and other Psychotic Disorders. Neuropsychopharmacology.2009 34:204-12164. Goldstein RB, Storch EA, Lehmkuhl H, Geffken GR, Goodman WK, Murphy TK. Successful medicationwithdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessivecompulsivedisorder.Depress Anxiety. 2009;26(1)165. Goodman WK, Insel TR. Deep brain stimulation in psychiatry: concentrating on the road ahead. Biol Psychiatry.2009 Feb 15;65(4):263-6.166. Merlo LJ, Storch EA, Lehmkuhl HD, Jacob ML, Murphy TK, Goodman WK, Geffken GR. Cognitive BehavioralTherapy Plus Motivational Interviewing Improves Outcome for Pediatric Obsessive-Compulsive Disorder: APreliminary Study. Cogn Behav Ther.2009 Aug 12:1. [Epub ahead of print] PubMed PMID: 19675960.167. Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH,Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessivecompulsivedisorder. J Affect Disord. 2009 Jul 2. [Epub ahead of print] PubMed PMID: 19577308.Updated 12/12/2009

168. Storch EA, Khanna M, Merlo LJ, Loew BA, Franklin M, Reid JM, Goodman WK, Murphy TK. Children's FloridaObsessive Compulsive Inventory: psychometric properties and feasibility of a self-report measure of obsessivecompulsivesymptoms in youth. Child Psychiatry Hum Dev. 2009 Sep;40(3):467-83. Epub 2009 Mar 27. PubMedPMID: 19326209.169. Burdick A, Goodman WK, Foote KD. Deep brain stimulation for refractory obsessive-compulsive disorder. FrontBiosci. 2009 Jan 1;14:1880-90. Review. PubMed PMID: 19273170.170. Lack CW, Storch EA, Keeley ML, Geffken GR, Ricketts ED, Murphy TK, Goodman WK. Quality of life inchildren and adolescents with obsessive-compulsive disorder: base rates, parent-child agreement, and clinicalcorrelates. Soc Psychiatry Psychiatr Epidemiol. 2009 Nov;44(11):935-42. Epub 2009 Mar 3. PubMedPMID:19255701.171. Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Martin P, Shapira NA, Wu S,Rasmussen SA and Okun MS. Deep Brain Stimulation for Intractable Obsessive Compulsive Disorder:Pilot Study using a Blinded, Staggered-Onset Design. Biological Psychiatry (in press)Books:1. Montgomery SA, Goodman WK, Goeting N (eds.): Current Approaches in Obsessive Compulsive Disorder.Southampton, UK: Ashford Colour Press for Duphar Medical Relations, 1990.2. Hand I, Goodman WK, Evers U (eds.): Obsessive Compulsive Disorders. New Research Results, Volume 5.Berlin/Heidelberg: Springer-Verlag, 1992.3. Goodman WK, Rudorfer M, Maser J (eds): Obsessive Compulsive Disorder: Contemporary Issues in Treatment.Lawrence Erlbaum Associates, 2000.Reviews, Chapters:1. Goodman W, Charney D, Heninger G, Price L, Woods S: Clinical spectrum of action of tricyclic antidepressants:Possible relationships to receptor actions. In: Shagass C, et al. (eds), Biol Psychiatry 1985, (Proceedings of the IV thWorld Congress of Biological Psychiatry), Elsevier, NY, pp. 906-908, 1986.2. Woods S, Charney D, Heninger G, Goodman W: Dysregulation of noradrenergic neuronal systems in panicdisorders. In: Shagass C, Josiassen R, Bridger W, Weiss K, Stoff D, Simpson G (eds), Biol Psychiatry, 1985,(Proceedings of the IVth World Congress of Biological Psychiatry), Elsevier, NY, pp. 796-798, 1986.3. Goodman WK, Charney DS, Rasmussen SA, Price LH, Woods SW, Heninger GR: The role of noradrenergic andserotonergic systems in obsessive compulsive disorder: Findings from pharmacological challenge studies. In theProceedings of the 6th Intern Catecholamine Symposium, Jerusalem, Israel, June 14-19, 1987.4. Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR: The specificity of noradrenergicdysregulation in panic disorder. In the Proceedings of the 6th Intern Catecholamine Symposium, Jerusalem, Israel,June 14-19, 1987.5. Goodman WK, Price LH: Antidepressants in obsessive compulsive disorder. Yale Psychiatric Quarterly 11:8-12,1988.6. Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR. Specificity of noradrenergicdysregulation in panic disorder. In: Progress in Catecholamine Research, Part C: Clinical Aspects, Belmaker RH,Sandler M, Dahlstrom A (eds), Alan R Liss, Inc: New York, pp. 343-347, 1988.7. Krystal JH, Goodman WK, Woods SW, Charney DS: Anxiety disorders. In: Lazare A (ed), Outpatient Psychiatry,Diagnosis and Treatment, 2nd Edition, New York, Williams and Wilkins Press, pp. 416-454, 1989.8. Heninger G, Charney D, Price L, Delgado P, Woods S, Goodman W: Effects of serotonergic agonists onneuroendocrine responses in rhesus monkeys and patients with depression and anxiety disorders. In: Dahl S, GramL (ed.), Clinical Pharmacology in Psychiatry. Berlin: Springer-Verlag, pp. 94-104, 1989.9. Goodman WK, Price LH, Rasmussen SA, Heninger GR, Charney DS. Fluvoxamine as an antiobsessional agent.Psychopharmacol Bull 25:31-35, 1989.10. McDougle CJ, Goodman WK: Obsessive Compulsive Disorder: Recent Neurobiological Developments, CurrentOpinions in Psychiatry 3:239-244, 1990.11. Charney D, Woods S, Price L, Goodman W, Glazer W, Heninger G: Noradrenergic dysregulation in panic disorder. In:Bodis-Wollner I, Zimmerman EA, (eds), Neurobiology of Panic Disorder, Frontiers of Clinical Neuroscience Series,NY:Alan R. Liss, pp. 91-105, 1990.12. Heninger G, Charney D, Price L, Delgado P, Woods S, Goodman W: Neuroendocrine effects of serotonin agonists inUpdated 12/12/2009

hesus monkeys, healthy humans and patients with depression or anxiety disorders: effects of antidepressant treatment.In: Paoletti R et al. (ed), Serotonin: From Cell Biology to Pharmacology and Therapeutics, Kluwer Acad Pub, pp. 559-563, 1990.13. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR: Clinical data on the roleof serotonin in the mechanism(s) of action of antidepressant drugs. J Clin Psychiatry 51(4, supp):44-50, 1990.14. Goodman W, Price L: Rating scales for obsessive compulsive disorder. In: Jenike M, Baer L, Minichiello W (eds),Obsessive Compulsive Disorders: Theory and Management, 2 nd Ed. PSG Publishing Company, Littleton, MA, pp.154-166, 1990.15. Goodman WK: Fluvoxamine in the treatment of OCD. In: Montgomery S, Goodman W, Goeting N (eds.), CurrentApproaches in Obsessive Compulsive Disorder. Southampton, UK: Ashford Colour Press for Duphar Med. Relations,pp. 64-73, 1990.16. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR: Clinical studies of 5-HT function using i.v. L-tryptophan. Prog. Neuro-Psychopharmacol. & Biol Psychiatry 14:459-472, 1990.17. Goodman WK, McDougle CJ: Serotonin reuptake inhibitors in obsessive compulsive disorder. Ann Clin Psych2(3):173-181, 1990.18. Goodman WK, Price LH, Woods SW, Charney DS: Pharmacological challenges in obsessive compulsive disorder. In:Zohar J, Insel T, Rasmussen S (eds), The Psycho-biology of Obsessive Compulsive Disorder. NY:Springer Pub. Co., pp.162-186, 1991.19. Goodman WK, Price LH: Fluvoxamine in the treatment of obsessive-compulsive disorder. In: Pato MT, Zohar J(eds), Current Treatments of Obsessive Compulsive Disorder. Washington, D.C.: American Psychiatric Press, pp.45-59, 1991.20. McDougle CJ, Goodman WK: Obsessive-compulsive disorders: Pharmacotherapy and pathophysiology. CurrentOpinion in Psychiatry 4, 267-272, 1991.21. McDougle CJ, Goodman WK: Studies in fluvoxamine in OCD. In: Symposium: Rational Pharmacotherapy inobsessive compulsive disorders: From animal models to studies in man, 5th World Congress of BiologicalPsychiatry. Florence, Italy. June 9-14, 1991. Biol Psychiatry, 1:671-674, Elsevier Science Publisher, 1991.22. Boyarsky BK, Perone LA, Lee NC, Goodman WK: Current treatment approaches to obsessive compulsive disorder.Archives Psychiatric Nursing 5:299-306, 1991.23. King R, Riddle M, Goodman W: The psychopharmacology of obsessive-compulsive disorder in Tourette Syndrome.In: Chase T, Friedhoff A, Cohen D (eds), Advances in Neurology, Vol. 58. New York: Raven Press, Ltd., pp. 283-291, 1992.24. Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS. The serotonin hypothesis of obsessive compulsivedisorder: Implications of pharmacologic challenge studies. J Clin Psych 53[4,suppl]:17-28, 1992.25. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive compulsive disorder. J Clin Psych53[4,suppl]29-37, 1992.26. Goodman WK: Pharmacotherapy of obsessive compulsive disorder. In: Hand I, Goodman WK, Evers U (eds.):Obsessive Compulsive Disorders. New Research Results, Volume 5. Berlin/Heidelberg: Springer-Verlag, pp. 141-151, 1992.27. Goodman W, McDougle C, Price L: The role of serotonin and dopamine in the pathophysiology of OCD. Int ClinPsychopharmacol 7(1):35-38, 1992.28. McDougle CJ, Goodman WK, Price LH. New research on the neurobiology of obsessive compulsive disorder. Curr.Opin. Psychiatry 5:249-254, 1992.29. Goodman WK, Price LH. Assessment of severity and change in obsessive compulsive disorder. In: ObsessionalDisorders. In Jenike MA (ed), Psychiatric Clinics of North America, Vol 15(4). WB Saunders: Philadelphia, pp. 861-869, 1992.30. McDougle CJ, Goodman WK, Leckman JF, Price LH. The psychopharmacology of obsessive compulsivedisorder: Implications for treatment and pathogenesis. Chapter in: Psychopharmacology II. In the series:Psychiatric Clinics of North America, Dunner DL (ed),WB Saunders: Philadelphia, pp. 749-766, 1993.31. McDougle CJ, Goodman WK, Price LH. The pharmacotherapy of obsessive compulsive disorder.Pharmacopsychiatry, 26:24-29, 1993.32. Goodman WK, McDougle CJ, Barr LC, Aronson S, Price LH. Biological approaches to treatment-resistantobsessive compulsive disorder. J Clin Psych, 54:6(suppl):16-26, 1993.33. Barr LC, Goodman WK, Price LH. Serotonin hypothesis of obsessive compulsive disorder. Int ClinPsychopharmacol, 8(suppl 2):79-82, 1993.Updated 12/12/2009

34. Goodman WK: Obsessive compulsive disorder. 1994 World Book Encyclopedia Health & Medical Annual,Chicago: World Book Inc, 431-466, 199435. Goodman WK, Rasmussen SA, Foa EB, Price LH: Obsessive compulsive disorder. Chapter 8: In Prien RF &Robinson DS (eds), Clinical Evaluation of Psychotropic Drugs: Principles and Guidance. New York: Raven Press,Ltd., pp 431-466, 1994.36. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum OCD. J ClinPsych 55[3, suppl]:24-31, 1994.Price LH, Goddard AW, Barr LC, Goodman WK. Pharmacological challenges inanxiety disorders. In: Bloom FE & Kupfer DJ (eds), Psychopharmacology: The 4 th Generation of Progress. NewYork: Raven Press, Ltd., 1311-1323, 1995.37. Goodman WK, Ward H, Kablinger A, Murphy T: Fluvoxamine in the treatment of obsessive-compulsive disorderand related conditions. J Clin Psychiatry 58:32-49 (suppl 5), 1997.38. McDougle CJ, Goodman WK: Combination pharmacological treatment strategies. In: Obsessive compulsivedisorders: Diagnosis, etiology, and treatment, pp. 203-223. Hollander E, Stein D (eds), Marcel Decker, Inc., NewYork, 1997.39. Goodman WK, Ward HE, Kablinger AS, Murphy TK: Obsessive compulsive disorder: Medical approaches totreatment-resistant cases. In Medscape Mental Health, 1997.40. Goodman WK, Ward HE, Murphy TK. Biological approaches to treatment-refractory obsessive compulsivedisorder. Psych Annals, 28(11) 641, 1998.41. Goodman WK, Murphy T: Obsessive compulsive disorders and Tourette’s syndrome. Ch. 6 in PharmacologicalManagement of Neurological and Psychiatric Disorders. Enna SJ & Coyle JT (eds) McGraw-Hill, pp. 177-211,1998.42. McDougle CJ, Barr LC, Goodman WK, Price LH: The role of neuropeptides in Obsessive Compulsive Disorder.Psychoneuroendocrinology, 24(1) 1-24, 1999.43. Goddard AW, Woods SW, Money R, Pande AC, Charney DS, Goodman WK, Heninger GR, Price LH: Effects ofthe CCKB Antagonist CI-988 on Responses to MCPP in Generalized Anxiety Disorder. Psychiatry Research, 85/3,225-240, 1999.44. Goodman WK: Obsessive-Compulsive Disorder: Diagnosis and Treatment. J Clin Psychiatry, 60 (Suppl) 18:27-32.1999.45. Goodman WK; New Strategies for the Management of Obsessive Compulsive Disorder; CNS News, 2 (6):11-14,June 2000.46. Goodman WK, Ward HE, Kablinger AS, Murphy TK: Biological approaches to treatment-resistant obsessivecompulsive disorder. In Obsessive Compulsive Disorder: Contemporary Issues in Treatment. WK Goodman, MD,MV Rudorfer, J Maser (eds) Lawrence Erlbaum Associates, NY, 2000.47. Byerly M, Goodman W, Cuadros C: Comorbid schizophrenia: Implications for treatment of OCD. In ObsessiveCompulsive Disorder: Contemporary Issues in Treatment. W Goodman, M Rudorfer, J Maser (Eds) Lawrence ErlbaumAssoc, NY, 2000.48. Goodman WK, McDougle CJ, Byerly MJ, Murphy TK, Ward HE: New Approaches to Treatment-RefractoryObsessive Compulsive Disorder; In: Pharmacotherapy for Mood, Anxiety and Cognitive Disorders, Chapter 31, pp479-498; Halbreich U and Montgomery S (eds), American Psychiatric Press, Washington DC, 2000.49. Goodman WK, Price LH, Stein DJ: Fluvoxamine in obsessive-compulsive disorder, in Zohar J, Pato MT (eds.),Current Concepts in Obsessive-Compulsive Disorder, 2nd edition. Washington, DC: American Psychiatric Press,200150. Murphy TK, Petitto J, Voeller KS, Goodman WK: Obsessive compulsive disorder: Is there an association withchildhood streptococcal infections and altered immune function? Semin in Clin Neuropsychiatry, 6(4):266-276,2001.51. Stein D, Seedat S, Shapira N, Goodman W. Management of Treatment-Resistant Obsessive-Compulsive Disorder inCurrent Treatments of Obsessive-Compulsive Disorder, 2 nd Edition (pp. 221-237). APA Publishing, Inc.,Washington, DC, 2001.52. Goldsmith TD, Shapira NA, Goodman WK. Methods of Assessment of OCD in Marazzitti D, Stein D, Fineberg D.(Eds.) Obsessive Compulsive Disorders: A Practical Guide to Management. Martin Dunitz Publishers, London,2001.53. Goodman WK: Pharmacotherapy of Obsessive Compulsive Disorder. In Textbook of Anxiety Disorders. Chapter16; Stein D & Hollander E (eds) American Psychiatric Press, 2002.54. Ward HE, Shapira NA, Goodman, WK: Nonpharmacological Somatic Treatments of Anxiety Disorders. PrimaryUpdated 12/12/2009

Psychiatry, 9(7):55-58, 2002.55. Culpepper L, Davidson JRT, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL: Suicidality as a Possible SideEffect of Antidepressant Treatment. Prim Care Companion J Clin Psychiatry, 6(2):79-86, 2004.56. Goodman WK: Selecting Pharmacotherapy for Generalized Anxiety Disorders. J Clin Psychiatry, 65(Suppl 13):8-13, 2004.57. Husted DS, Shapira NA, Goodman WK: Obsessive-Compulsive Disorder in Tarazi FI and Schetz JA: Manual ofNeuropsychiatric Disorders. Humana Press, 2005.58. Merlo LJ, Storch EA, Murphy TK, Goodman WK, Geffken GR. Assessment of pediatric obsessive-compulsivedisorder: a critical review of current methodology. Child Psychiatry Hum Dev, 36(2):195-214, 2005.59. Lewin A, Storch EA, Adkins J, Merlo L, Murphy TK, Goodman WK, Geffken GR. Update and review on pediatricobsessive-compulsive disorder. Psychiatric Annals, 35, 745-751, 2005.60. Larson MJ, Storch EA, Lewin AB, Geffken GR, Murphy TK, Goodman WK. Treatment of pediatric obsessivecompulsivedisorder: A review. Current Psychiatry Reviews, 1:281-292, 2005.61. Goodman WK, Murphy TK, Lazoritz M. Risk of suicidality during antidepressant treatment of children andadolescents. Primary Psychiatry, 13(1):43-50, 2006.62. Lewin A, Storch EA, Geffken GR, Goodman WK, Murphy TK. A neuropsychiatric review of pediatric obsessivecompulsivedisorder: etiology and efficacious treatments. Neuropsychiatric Disease and Treatment,2(1), 2006.63. Husted DS, Shapira NA, Goodman WK. The neurocircuitry of obsessive-compulsive disorder and disgust. ProgNeuropsychopharmacol Biol Psychiatry. May;30(3):389-99, 2006.64. Murphy TK, Sajid MW, Goodman WK. Immunology of obsessive-compulsive disorder. Psychiatr Clin North Am,29(2):445-69, 2006.65. Skidmore FM, Rodriguez RL, Fernandez HH, Goodman WK, Foote KD, Okun MS. Lessons learned in deep brainstimulation for movement and neuropsychiatric disorders. CNS Spectr, 11(7):521-36, 2006.66. Goodman WK, Storch EA, Geffken GR, Murphy TK. Obsessive-Compulsive Disorder in Tourette Syndrome. JChild Neurol. 2006 Aug;21(8):704-14..67. Goodman WK, Murphy TK, Storch EA. Risk of adverse behavioral effects with pediatric use ofantidepressants. Psychopharmacology (Berl), 191(1):87-96, 2007.68. Goodman WK, Lydiard RB. Recognition and treatment of obsessive-compulsive disorder. J ClinPsychiatry.;68(12):e30. 200769. Murphy TK, Segarra A, Storch EA, Goodman WK.SSRI adverse events: how to monitor and manage.IntRev Psychiatry. (2):203-8. 200870. Sallinen B, Storch EA, Murphy TK, Goodman WK, Geffken GR. University of Florida Obsessive-Compulsive Disorder Program: Exploring the option of intensive cognitive-behavioral therapy. FloridaPsychologist, (2008 XX).71. Fernandez MA, Storch EA, Murphy TK, Geffken GR, Goodman WK. Contemporary research and issues inthe treatment of Obsessive-Compulsive Disorder with Cognitive-Behavioral Therapy. Psychiatrics, (in pressXX).Miscellaneous:1. Goodman WK, (Primary Consultant). Clomipramine for obsessive compulsive disorder. Medical Letter 30:102-104,1988.2. Goodman WK, Price LH: Guidelines to the diagnosis of obsessive compulsive disorder. Diagnostic TreatmentGuide for OCD, a CIBA-GEIGY publication, 1989.3. Price LH, Goodman WK: Obsessive-compulsive disorder: A treatment review [Letter]. J Clin Psych 50:231-232,1989.4. McDougle CJ, Goodman WK, Delgado PL, Price LH: Pathophysiology of OCD [Letter], Am J Psychiatry146:1350-1351, 1989.5. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR: Neuroleptic additionin fluvoxamine-refractory obsessive compulsive disorder. Yale Psychiatr Quart 12(1):9-10, 1989.6. McDougle C, Price L, Goodman W, Charney D, Heninger G: Lithium augmentation in fluvoxamine-refractoryOCD. Yale Psychiatr Quart 13(3+4):15-16, 1990.7. Goodman WK, Price LH: In reply to "Desensitization of terminal 5-HT autoreceptors by 5-HT reuptake blockers."[Letter ]. Arch Gen Psychiatry 48:484, 1991.8. Barr LC, Goodman WK, Price LH: Acute exacerbation of body dysmorphic disorder during tryptophan depletionUpdated 12/12/2009

[Letter]. Am J Psychiatry 149:1406-1407, 1992.9. Goodman WK. The diagnosis of OCD. Focus on OCD 1(1):2-3, 199310. Barr LC, Price LH, Goodman WK, Physical symptoms associated with paroxetine discontinuation [Letter]. Am JPsychiatry, 151; 289, 1994.11. Byerly M, Goodman W, Christensen R: High doses of sertraline for treatment-resistant obsessive-compulsivedisorder [Letter]. Am J Psychiatry 153:1232-1233, 1996.12. Jenike MA, Rauch SL, Cummings JL, Savage CR, Goodman WK: Recent developments in neurobiology ofobsessive-compulsive disorder. Academic Highlights J Clin Psychiatry 57(10):492-495, 1996.13. McDougle CJ, Barr LC, Goodman WK, Price LH: Possible role of neuropeptides in obsessive compulsive disorder.Psychoneuroendocrinology Jan;24(1):1-24, 1999.14. Van Wattum PJ, Anderson GM, Goodman WK, Riddle MA, Leckman JF. Cerebrospinal Fluid Dynorphin A[1-8]and ß-Endorphin Levels in Tourette’s Syndrome Are Unaltered. [Letter] Bio. Psych., Jun 1;45(11):1527-8, 1999.15. Murphy TK, Goodman WK. Neuropsychiatric Disorders: The Neuroimmunological Link? Editorial, CNSSpectrums, 2001 May; 6 (5):378.16. Goodman WK (moderator), Barbee JG and Sheehan DV (discussants). Anxiety Disorders: Panic, GeneralizedAnxiety, & Obsessive-Compulsive Disorders. CME Program by Washington University School of Medicine, St.Louis, MO. March 2004.17. Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL: Suicidality as a Possible Side Effectof Antidepressant Treatment. [CME] J Clin Psych, 65(6):742, 2004.18. Pallanti S, Hollander E, Goodman WK: A Qualitative Analysis of Nonresponse: Management of Treatment-Refractory Obsessive-Compulsive Disorder. [CME] J Clin Psych, 65(Suppl 14):6-10, 2004.19. Goodman WK: Obsessive Compulsive Disorder. In Glick ID, Balon R, Zisook S, et al., ASCP ModelPsychopharmacology Curriculum, 4 th Edition, American Society of Clinical Psychopharmacology, Glen Oaks, NY,2006.20. Goodman WK, Lydiard RB. Recognition and treatment of obsessive-compulsive disorder. J Clin Psych,Dec;68(12):e30, 2007.21. Goodman, WK. “Obsessive Compulsive Disorder”. In Glick ID, BalonR, Zisook S, et al., ASCP ModelPsychopharmacology Curriculum, 5 th Edition, American Society of Clinical Psychopharmacology, Glen Oaks, NY,2008Abstracts:1. Woods SW, Charney DS, Heninger GR, Goodman WK, Loke J, Redmond DE Jr: Mechanisms of C02-inducedanxiety. Society for Neuroscience Annual Meeting Abstracts 11:132, 1985.2. Charney DS, Woods SW, Goodman WK, Heninger GR: The regulation of noradrenergic function in depressive andanxiety disorders. Abstracts of the IVth World Congress of Biological Psychiatry, Philadelphia, 1985.3. Charney DS, Heninger GR, Price LH, Goodman WK, Woods SW: Clinical spectrum of action of tricyclicantidepressants: Possible relationships to receptor actions. World Congress of Biological Psychiatry, Philadelphia,1985.4. Charney DS, Heninger GR, Woods SW, Goodman WK: Dysregulation of Noradrenergic Neuronal Systems in PanicDisorders. World Congress of Biological Psychiatry, Philadelphia, 1985.5. Woods SW, Charney DS, Goodman WK, Heninger GR: Effects of Alprazolam on C02-induced anxiety. WorldCongress of Biological Psychiatry, Philadelphia, 1985.6. Woods S, Goodman W, Charney D: NE Hyperactivity associated with yohimbine panic. New Research Abstracts,American Psychiatric Assoc (APA) Annual Meeting, #NR 7, May, 1986.7. Charney DS, Woods SW, Goodman WK, Heninger GR: Noradrenergic function in panic disorders. APA AnnualMeeting, #107C, pp 192, May, 1986.8. Goodman WK, Price LH, Rasmussen SA, Charney DS, Woods SW, Heninger GR: Evidence for abnormalserotonergic function in obsessive compulsive disorder. Society for Neuroscience Annual Meeting Abstracts Vol.12, pp 1161, 1986.9. Charney DS, Woods SW, Goodman WK, Heninger GR: Abnormal regulation of noradrenergic function in panicdisorders. Soc Neurosci Abstracts pp 1162, 1986.10. Goodman W, Charney D, Price L, Rasmussen S, Heninger G, Delgado P, Krystal J: Fluvoxamine in obsessivecompulsive disorder. New Research Abstracts, American Psychiatric Association (APA) Annual Meeting, #NRUpdated 12/12/2009

183, pp 118, 1987.11. Goodman WK, Charney DS, Rasmussen SA, Price LH, Woods SW, Heninger GR: Serotonin and OCD. APAAnnual Meeting, Symposium, #12C, pp 47, 1987.12. Charney DS, Woods SW, Goodman WK, Heninger GR: Neurobiological mechanisms of panic anxiety. APAAnnual Meeting, Symposium, #103C, pp 188, 1987.13. Heninger GR, Charney DS, Woods SW, Price LH, Goodman WK: Serotonergic agonists in anxiety and depression.APA Annual Meeting, #95D, pp 175, 1987.14. Charney DS, Woods SW, Goodman WK, Heninger GR: Neurobiological mechanisms of panic anxiety. APAAnnual Meeting, Symposium, #68C, pp 130, 1987.15. Woods SW, Charney DS, Krystal JH, Goodman WK, Heninger GR: The carbon dioxide- induced anxiety state.APA Annual Meeting, Symposium, #67E, pp 129, 1987.16. Charney DS, Woods SW, Goodman WK, Krystal JH, Nagy LM, Heninger GR: The efficacy of lorazepam in panicdisorders. New Research Abstracts, APA Annual Meeting, #NR 165, pp 110, 1987.17. Goodman WK, Charney DS, Price LH, Delgado PL, Rasmussen SA, Heninger GR: Fluvoxamine in OCD:Antiobsessional or antidepressant? Society for Neuroscience Annual Meeting Abstracts, No. 66.8, pp 215, 1987.18. Leckman JF, Pauls DL, Hurst CR, Riddle MA, Towbin KE, Goodman WK, Rasmussen SA, Anderson G, CohenDJ: The relationship between obsessive compulsive disorder and Gilles De La Tourette's syndrome. AmericanCollege of Neuropsychopharmacology (ACNP) Annual Meeting, 1987.19. Goodman WK, Rasmussen SA, Mazure C, Charney DS: Measurement of treatment response in OCD: Use andvalidation of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). ACNP Annual Meeting, 1987.20. Goodman WK, Price L, Rasmussen SA, Mazure C, Heninger GR, Charney DS: Yale-Brown Obsessive CompulsiveScale: Validity. New Research Abstracts, American Psychiatric Association (APA) Annual Meeting, #NR261, pp128, 1988.21. Goodman WK, Price LH, Charney DS, Heninger GR: Fluvoxamine in OCD. Collegium Internationale Neuro-Psychopharmacologicum Meeting, 1988.22. Goodman WK, Price LH, Anderson GM, Delgado PL, Palumbo JM, Heninger GR, Charney DS: Serotonergic drugaction and the treatment of OCD. Society for Neuroscience Annual Meeting Abstracts, 14(1), pp 372 (152.1), 1988.23. Delgado PL, Charney DS, Price LH, Goodman WK, Aghajanian GK, Landis H, Heninger GR: Behavioral effects ofacute tryptophan depletion in depressed and obsessive compulsive disorder (OCD) patients. Soc Neurosci Abstracts14(2):970 (390.20), 1988.24. Charney DS, Price LH, Delgado PL, Woods SW, Goodman WK, Heninger GR: Monoamine receptor function inaffective disorders. Proceedings of the American Psychiatric Association (APA) Annual Meeting, Symposium 19C,pp 145, 1988.25. Goodman WK, Price LH, Heninger GR, Charney DS: Pharmacological treatment of OCD. APA Annual Meeting,Symposium, #47F, pp 190, 1988.26. Goodman W, Price H, Rasmussen S, Delgado P, Heninger G, Charney D: Fluvoxamine treatment of obsessivecompulsive disorder. APA Annual Meeting, Symp#93D, pp 260, 1988.27. Goodman W, Price L, Delgado P, Rasmussen S, Palumbo J, Charney D, Heninger G: Fluvoxamine in the treatmentof OCD. New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Key Biscayne, FL, 1988.28. Leckman JF, Riddle MA, Goodman WK, Berrettini WH, Chappell P, Anderson GM: CSF Dynorphin A(1-8) inTourette's Syndrome and Obsessive Compulsive Disorder. American College of Neuropsychopharmacology(ACNP) Annual Meeting, 1988.29. Heninger GR, Charney DS, Price LH, Woods SW, Goodman WK: Neuroendocrine and behavioral effects of 5-HTagonists in rhesus monkeys, and patients: The effects of lithium. ACNP Annual Meeting, p 76, 1988.30. Goodman W, Delgado P, Price L, Palumbo J, Rasmussen S, Charney D: Comparison of fluvoxamine anddesipramine in OCD. ACNP Annual Meeting, p 144, 1988.31. Delgado PL, Goodman WK, Price LH, Landis H, Aghajanian GK: Behavioral effects of acute Tryptophan-depletionin depressed and obsessive compulsive disorder (OCD) patients. ACNP Annual Meeting, p 184, 1988.32. Goodman WK, Delgado PL, Price LH, Palumbo J, Rasmussen SA, Charney DS: Fluvoxamine versus desipramine inOCD, New Research Abstracts, Proceedings of the American Psychiatric Association (APA) Annual Meeting,#NR343, p.186, 1989.33. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR: Neuroleptic additionin fluvoxamine-refractory OCD, New Research Abstracts, APA Annual Meeting, #NR350, p. 189, 1989.34. Delgado PL, Goodman WK, Price LH, Charney DS, Aghajanian GK, Heninger GR: Tryptophan depletion altersUpdated 12/12/2009

mood in OCD patients, New Research Abstracts, APA Annual Meeting, #NR351, p. 190, 1989.35. Pauls DL, Goodman WK, Rasmussen SA, Leckman JF: The inheritance and expression of obsessive compulsivebehaviors, APA Annual Meeting, Industry Symposium #8D, p. 26, 1989.36. Charney DS, Goodman WK: Psychopharmacological treatments of obsessive compulsive disorder, APA AnnualMeeting, Industry Symposium #20D, p. 40, 1989.37. Goodman WK, Price LP, Anderson GM, Palumbo JH, Charney DS, Heninger GR: Drug response and obsessivecompulsive disorder subtypes, APA Annual Meeting, Symposium #5C, p. 134, 1989.38. Leckman JF, Riddle MA, Goodman WK, Berrettini WH, Chappell PB, Anderson GM: CSF dynorphin A (1-8) inTourette's syndrome and obsessive compulsive disorder, APA Annual Meeting, Symposium #36E, p. 181, 1989.39. Goodman WK, Price LH, Charney DS: Fluvoxamine vs. desipramine in OCD, Joint Meeting of British Associationfor Psychopharmacology & Interdisciplinary Society of Biological Psychiatry, Cambridge, England, 1989.40. Goodman WK, Price LH, McDougle CJ, Riddle MA, Hoffer PB, Woods SW: SPECT regional cerebral blood flowin OCD, Society for Neuroscience Annual Meeting Abstracts, #179.12, p. 448, 1989.41. Delgado PL, Charney DS, Price LH, Goodman WK, Aghajanian GK, Heninger GR: Behavioral effects of acutetryptophan depletion in psychiatric patients and healthy subjects, Soc Neurosci Abstracts, #166.13, p. 412, 1989.42. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR: Addition ofdopamine antagonists in fluvoxamine-refractory obsessive compulsive disorder. Soc Neurosci Abstracts, #109.20,p. 271, 1989.43. Goodman WK, Rasmussen SA, Price LH: Type of obsessive-compulsive symptoms and response to clomipramine.American College of Neuropsychopharmacology (ACNP) Annual Meeting, #6, p. 78, 1989.44. McDougle C, Goodman W, Price L: Lithium augmentation in fluvoxamine-refractory obsessive compulsivedisorder. ACNP Annual Meeting, #7, p. 78, 1989.45. Delgado PL, Charney DS, Price LH, Goodman WK, Aghajanian GK, Seibyl J, Heninger GR: Behavioral effects ofrapid tryptophan depletion in psychiatric patients and healthy subjects. ACNP Annual Meeting, #131, p. 93, 1989.46. Goodman W: Clinical evidence implicating the basal ganglia in obsessive compulsive disorder. ACNP AnnualMeeting, "The Role of the Basal Ganglia in Tourette's Syndrome and Obsessive Compulsive Disorder," 1989.47. Goodman WK, Rasmussen SA, Price LH: Types of symptoms and response to clomipramine in obsessivecompulsive disorder. New Research Abstracts, Proceedings of the American Psychiatric Association (APA) AnnualMeeting, #NR169, 1990, p. 112.48. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR: Lithium augmentation in fluvoxaminerefractory obsessive compulsive disorder. New Research Abstracts, APA Annual Meeting, #NR302, 1990, p. 163.49. Wexler BE, Goodman WK: Imbalance between the cerebral hemispheres in OCD. New Research Abstracts, APAAnnual Meeting, #NR331, 1990.50. Goodman WK, Price LH, Delgado PL, McDougle CJ, Charney DS, Heninger GR: Fluvoxamine and the mechanismof anti-obsessive compulsive disorder action, APA Annual Meeting, Symposium, #1, p. 88, 1990.51. Goodman WK, McDougle CJ, Price LH, Charney DS, Heninger GR. Lithium augmentation in fluvoxaminerefractoryobsessive compulsive disorder. Society for Neuroscience Annual Meeting Abstracts. 16(2):#377.21, p.916, 1990.52. Holzer JC, Boyarsky BK, McDougle CJ, Lee N, Price LH, Goodman WK. Differential symptoms in OCD with andwithout a tic disorder. American College of Neuropsychopharmacology (ACNP) Annual Meeting, p. 195, 1990.53. Riddle MA, Rasmussen AM, Woods SW., Goodman WK, Leckman JF, Smith EO, Hardin MT, Hoffer PB. SPECTimaging of regional cerebral blood flow in Tourette's syndrome. ACNP Annual Meeting, p. 196, 1990.54. McDougle CJ, Goodman WK, Price LH, Holzer JC, McCance-Katz EF, Heninger GR: Buspirone addition influvoxamine-refractory OCD. New Research Abstracts, Proceedings of the American Psychiatric Association(APA) Annual Meeting, #NR328, p. 126, 1991.55. Holzer J, Price L, McDougle C, Boyarsky B, Goodman W. Symptoms in OCD with and without TIC disorder. NewResearch Abstracts, APA Annual Meeting, #NR358, 1991.56. Goodman WK (Chair), McDougle CJ, Price LH, Charney DS, Heninger GR: Serotonin Reuptake Inhibitors inOCD.: Symposium #20: Serotonin hypothesis of OCD: a critical review. APA Annual Meeting, New Orleans, LA,1991.57. McDougle CJ, Goodman WK, Price LH, Heninger GR: Medication approaches to treatment-resistant OCD.Symposium #20: Serotonin hypothesis of OCD: a critical review. APA Annual Meeting, New Orleans, LA, 1991.58. Goodman WK (Chairperson), McDougle CJ, Price LH: Pharmacotherapy of OCD, Symposium #IS12: OCD:Integrating Theory and Practice, APA Annual Meeting, New Orleans, LA, 1991.Updated 12/12/2009

59. Goodman WK: Comorbidity of OCD and Other Axis I Disorders, Symposium #IS6: OCD: Spectrum andComorbidity. APA Annual Meeting, New Orleans, LA, 1991.60. Holzer J, Price L, McDougle C, Boyarsky B, Goodman W: Symptoms in OCD with and without a tic disorder.International Scientific Symposium on Tourette Syndrome, Boston, MA, 1991.61. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH: Efficacy of haloperidol addition influvoxamine-refractory obsessive compulsive disorder: A double-blind placebo-controlled study. American Collegeof Neuropsychopharmacology (ACNP) Annual Meeting, p. 183, 1991.62. Barr LC, Price LH, McDougle CJ, Delgado PL, Goodman WK: Acute tryptophan depletion in drug-remitted OCD.New Research Abstracts, Proceedings of the American Psychiatric Association (APA) Annual Meeting, #NR141,1992.63. Black J, Goodman W, Boyarsky B, Price L: Compulsive behaviors and cocaine. New Research Abstracts, APAAnnual Meeting, p 96, #NR180, 1992.64. Naylor ST, McDougle CJ, Goodman WK, Volkmar FR, Cohen DJ, Hawkins KA, Price LH: OCD symptoms inadults with autistic disorder. New Research Abstracts, APA Annual Meeting, #NR200, 1992.65. Goodman W, McDougle C, Price L, Barr L, Heninger G: Oral and parenteral mCPP in 12 patients with OCD. NewResearch Abstracts, APA Annual Meeting, #NR509, 1992.66. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH: Haloperidol addition in fluvoxaminerefractoryOCD. New Research Abstracts, APA Annual Meeting, p 172, #NR513, 1992.67. Goddard A, Goodman W, Woods S, Heninger G, Charney D, Price L. Effects of tryptophan depletion on panicanxiety. American College of Neuro-psychopharmacology (ACNP) Annual Meeting, p.150, 1992.68. Barr L, Price L, McDougle C, Delgado P, Goodman W. Acute tryptophan depletion exacerbates depressive, but notobsessive compulsive, symptoms in drug-remitted obsessive-compulsive disorder patients. ACNP Annual Meeting,p.154, 1992.69. Barr LC, Price LH, McDougle CJ, Delgado PL, Goodman WK. Effects of acute tryptophan depletion in drugremittedobsessive-compulsive disorder patients. Society for Neuro-science Annual Meeting Abstracts, 18(1):3(#7.3), 1992.70. Goodman WK, McDougle CJ, Barr LC, Price LH. Biological approaches to the treatment-refractory patient. FirstInternational Obsessive Compulsive Disorder Conference, Capri, Italy, 1993.71. Goodman WK, McDougle CJ, Price, LH. Pharmacotherapy of obsessive compulsive disorder. International OCDConference, Capri, Italy, 1993.72. Leckman J, Walker D, Goodman W, Rasmussen S, Pauls D, Cohen D. "Just right" perceptions associated withcompulsive behavior in Tourette's syndrome and obsessive compulsive disorder. International OCD Conference,Capri, Italy, 1993.73. Wexler BE, Yazgan Y, Barr L, Goodman W. Cerebral laterality, perception of emotion, and treatment response inobsessive-compulsive disorder. International OCD Conference, Capri, Italy, 1993.74. Barr LC, Aronson SC, Anand A, Price LH, Goodman WK. Clozapine in treatment resistant obsessive compulsivedisorder. Society for Neuroscience Annual Meeting Abstracts, 19(1):383(#158.6), 1993.75. Goddard A, Goodman W, Woods S, Heninger G, Charney D, Price L. Effects of tryptophan depletion on panicanxiety. Soc Neurosci Abstracts, Abstr. #244.2, p. 591, 1993.76. Chappell PB, Leckman JF, Goodman WK, Bissette G, Pauls DL, Anderson GM, Riddle MA, Scahill LD, Price LH,McDougle CJ, Barr LC, Cohen DJ. Elevated levels of CSF CRF in Tourette's syndrome: Comparison to obsessivecompulsive disorder and normal controls. American College of Neuropsychopharmacology (ACNP) AnnualMeeting, p 195, 1993.77. Leckman J, Goodman W, North W, Chappell P, Price L, Pauls D, Anderson G, Riddle M, McSwiggan-Hardin M,McDougle C, Barr L, Cohen D. Elevated levels of CSF oxytocin in OCD: Comparison with TS and healthycontrols. ACNP Annual Meeting, p 195, 1993.78. Goddard AW, Charney DS, Sholomskas D, Augeri F, Walton K, Woods, SW, Heninger GR, Price LH, GoodmanWK. Effects of tryptophan depletion on anxiety response to yohimbine in panic disorder. ACNP Annual Meeting, p107, 1993.79. Barr LC, Goodman WK, Heninger GR, Price LH. Vulnerability to the depressant effect of tryptophan depletion notconferred solely by antidepressant administration. ACNP Annual Meeting, p 107, 1993.80. Goodman, WK. Enhancing Recognition and Diagnosis of OCD: Introduction of a New Screening Test. In: GettingWell and Staying Well: Working Toward a Broader Understanding. Annual Anxiety Disorders Association ofAmerica (ADAA) Conference, Santa Monica, California, 1994.Updated 12/12/2009

81. Goodman WK, McDougle C, Barr L, Leckman J, Price LH. Serotonin/dopamine interaction in Tourette's syndromerelated OCD. In Symposium 40, "The Neurobiology and Treatment of Human Anxiety: Recent Advances."Proceedings of the American Psychiatric Association (APA) Annual Meeting, p 88, May 1994.82. Barr LC, Goodman WK, Anand A, Price. Desipramine augmentation of selective serotonin reuptake inhibitortreatment of refractory OCD. New Research Abstracts, APA Annual Meeting, p 213 (#NR602), 1994.83. Barr LC, Goodman WK, Heninger GR, Price LH. Effects of tryptophan depletion on mood during fluoxetinetreatment of healthy subjects. New Research Abstracts, APA Annual Meeting, p 213 (#NR603), 1994.84. Goodman WK. OCD and Comorbid Conditions. XIXth Collegium Internationale Neuro-Psychopharmacologicum(CINP) Congress, Washington, DC, June 1994.85. Goodman WK. Medications for OCD and the end of the Millennium, XIXth CINP Congress, Washington, DC,1994.86. Goodman WK. How do SRIs Really Work in OCD, XIXth CINP Congress, Washington, DC, 1994.87. Goodman WK. Developments in the Treatment of OCD. Symposium on Advances in OCD and Tourette's Syndrome.Joint Meeting of British Assoc. for Psychopharma-cology & Interdisciplinary Society of Biological Psychiatry.Cambridge, Eng. 1994.88. Goddard A, Charney D, Sholomskas D, Augeri E, Walton K, Woods S, Heninger G, Price L, Goodman W. Effectsof Tryptophan Depletion on Anxiety Responses to Yohimbine in Panic Disorder. Society for Neuroscience AnnualMeeting, Miami Beach, FL, 1994.89. Goddard AW and Goodman WK. Serotonin, norepinephrine or both in anxiety? Abstr. #23. Society of BiologicalPsychiatry Annual Meeting Abstracts, 53:621, 1994.90. Musil SY, Martinez SA, Drobes DJ, Cuthbert, BN, Goodman WK, Lang, PJ. Autonomic and startle respondingduring imagery and picture viewing in a patient pre- and post-anterior capsulotomy to relieve intractable obsessivecompulsivedisorder. Society for Neuroscience Annual Meeting, 1995.91. Epperson C, McDougle C, Brown R, Leckman J, Goodman W, Price L. OCD during pregnancy and puerperium.New Research Abstracts, Proceedings of the American Psychiatric Association (APA) Annual Meeting, p 84 (NR112) 1995.92. Brown RM, McDougle CJ, Epperson CN, Wasylink S, Goodman WK, Price LH. OCD and suicide: A systematicInvestigation. New Research Abstracts, APA Annual Meeting, p 85 (NR 116) 1995.93. Eisen JL, Rasmussen SA, Goodman WK, Warshaw M. Remission and Relapse in OCD: A two-year prospectivestudy. New Research Abstracts, APA Annual Meeting, p 155 (NR 367) 1995.94. Morris MR, Blashfield R, Rankupalli B, Goodman WK. Subclinical OCD in college students. New ResearchAbstracts, APA Annual Meeting, p 157 (NR 378) 1995.95. Goodman WK. Developments in the treatment of OCD. APA Annual Meeting, Symposium Abstr, p 260 (No. 18E)1995.96. Murphy T, Fudge M, Dalal M, Ayoub E, Williams R, Zabriskie, Goodman W: D8/17 Positivity in Childhood-OnsetOCD and/or TS. American College of Neuropsycho-pharmacology (ACNP) Annual Meeting, 1995.97. Leckman J, McDougle J, Goodman, W, Pauls, D: Identification of OCD subtypes. Society of Biological PsychiatryAnnual Meeting, NY, Abstr, 39(7):508, 1996.98. Howard WT, Blashfield RK, Goodman WK: Personality Disorders and OCD: A meta and citation analysis.Proceedings of the American Psychiatric Association (APA) Annual Meeting, Abstr NR65, New York City, 1996.99. Fudge MW, Murphy TK, Goodman WK, Williams Jr RC, Ayoub E. Frequency of D8/17 and antistreptococcalantibodies in patients with childhood onset OCD and/or Tourette’s syndrome. American Federation of ClinicalResearch, Southern Region, New Orleans, 1996.100. Goodman WK Obsessive-Compulsive Disorder: Diagnosis and Treatment. Proceedings of the American PsychiatricAssociation (APA) Annual Meeting, Abstr, Toronto, Canada, June 1998.101. Romano S, Goodman W, Tamura R, Gonzales J, Collaborative Research Group. Long-Term Treatment of ObsessiveCompulsive Disorder Following Acute Response: A comparison of fluoxetine vs. placebo. APA Annual Meeting,Toronto, CA, June 1998.102. Romano S, Goodman W, Tamura R., Gonzales J, and Collaborative Research Group. Long-Term Treatment of ObsessiveCompulsive Disorder Following Acute Response: A Comparison of Fluoxetine versus Placebo. European College ofNeuropsychopharmacology (ECNP) Congress, Paris, France, November 1998103. Romano S, Goodman W, Tamura R., Gonzales J, and Collaborative Research Group. Long-Term Treatment ofObsessive Compulsive Disorder Following Acute Response: A Comparison of Fluoxetine versus Placebo. AmericanCollege of Neuropsycho-pharmacology (ACNP) Annual Meeting, Las Croabas, PR, December 1998.Updated 12/12/2009

104. Morris MR, Forbes, S, Roberts M, Bradley MM, Goodman WK. Longitudinal course of subclinical obsessivecompulsive disorder in college students. American Psychiatric Association (APA) Annual Meeting, Washington,D.C., May 1999.105. Goodman W, Londborg P, Lydiard B, Hackett E, Rubin A, Wolkow R. Safety of sertraline in long-term OCDtreatment: Preliminary results of a multicenter study. APA Annual Meeting, Abstr NR65, Washington, D.C., May1999.106. Goodman W, Londborg P, Lydiard B, Hackett E, Rubin A, Wolkow R. Safety of sertraline in long-term OCDtreatment: Preliminary results of a multicenter study. NCDEU Annual Meeting, Boca Raton, FL, June 1999.107. Murphy T, Goodman WK, Torres BA, Ayoub EM. Altered immune indices in Pediatric OCD and/or TS. AmericanCollege of Neuropsychopharmacology (ACNP) Annual Meeting, December 1999.108. Murphy T, Goodman W, Torres B, Ayoub E. Autoimmune mechanisms in obsessive compulsive disorder andSydenham’s chorea. ACNP Annual Meeting, December 1999.109. Goodman WK: Refractory OCD. Annual Meeting of the International OCD Congress, St. Thomas, VI, February2000.110. Shapira N, Murphy T, Goldsmith T, Ward H, Wyllie E, Goodman W. Double-Blind Placebo-Controlled Trial ofTramadol Hydrochloride in Outpatients with Treatment-Refractory OCD. APA Research Colloquium for JuniorInvestigators, Chicago, IL, May 2000.111. Murphy T, Benson N, Zaytoun A, Yang M, Braylan R, Ayoub E, Goodman W. Progress toward analysis of D8/17binding to B cells in children with OCD and/or Chronic Tic Disorder, American College of Neuropsychopharmacology(ACNP) Annual Meeting, December 2000.112. Shapira NA, Driscoll DJ, McCune HC, Urfer LK, Goodman WK. Open-label pilot study of Topiramate in adultswith Prader-Willi syndrome. ACNP Annual Meeting, San Juan, PR, December 2000.113. Shapira NA, Lessig MC, McCune HC, Goodman WK, Driscoll DJ. Open-Label Pilot Study of Topiramate in Adultswith Prader-Willi Syndrome. Annual Anxiety Disorder Association of America Conference, Atlanta, March 2001.114. Shapira NA, Lessig MC, McCune HC, Goodman WK, Driscoll DJ. Open-Label Pilot Study of Topiramate in Adultswith Prader-Willi Syndrome. American Psychiatric Association (APA) Annual Meeting, New Orleans, May 2001.115. Liu Y, Bradley M, He G, Sabatinelli D, Shapira N, Stein DJ, Taeb Y, Mao J, Fitzsimmons J, Lang P, Goodman W.Brain Activation by “Disgust”-Inducing Visual Stimulation. Society For Neuroscience Annual Meeting, San Diego,CA, November 2001.116. Liu Y, Stein DJ, Shapira NA, Goodman WK. The Role of Disgust in Obsessive-Compulsive Disorder Assessed byFunctional MRI. American College of Neuro-psychopharmacology (ACNP) Annual Meeting, Waikoloa, Hawaii,December 2001.117. Shapira NA, Liu Y, Lessig MC, Bradley MM, He G, Sabatinelli D, Stein DJ, Taeb Y, Mao J, Fitzsimmons JR, LangPL, Goodman WK. Brain Activation by “Disgust”-Inducing Visual Stimulation in OCD. ACNP Annual Meeting,Waikoloa, HI, December 2001.118. George M, Ward H, Ninan P, Pollack M, Nahas Z, Goodman W, Knight B, Simon N, Ballenger J: Vagus NerveStimulation (VNS ) Shows Potential Therapeutic Benefit For Severe Anxiety Disorders In An Initial Open Trial.American College of Neuro-psychopharmacology (ACNP) Annual Meeting, San Juan, PR, December 2002.119. Goodman W, Bose A, Korotzer A, Wang Q. Escitalopram 10mg/day is effective in the treatment of generalizedanxiety disorder. ACNP Annual Meeting, San Juan, PR, December 2002.120. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. Placebo-Controlled Trial ofFluoxetine vs. Fluoxetine Plus Olanzapine in OCD. ACNP Annual Meeting, San Juan, PR, December 2002.121. Murphy TK, Sajid M, Soto O, Shapira N. Edge P, Yang M, Goodman W. Association of Group A Streptococcus byTiter Analysis in OCD and Tic Exacerbations. ACNP Annual Meeting, San Juan, PR, December 2002.122. George MS, Ward H, Ninan PT, Pollack MH, Nahas Z, Goodman WK, Ballenger JC. Open Trial of VNS Therapyin Severe Anxiety Disorders. American Psychiatric Association (APA) Annual Meeting, San Francisco, CA, May2003.123. Goodman WK. Escitalopram 10mg/day Is Effective in the Treatment of GAD. APA Annual Meeting, SanFrancisco, CA, May 2003.124. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. Placebo-Controlled Trial ofFluoxetine vs. Fluoxetine Plus Olanzapine in OCD. NCDEU Annual Meeting, Boca Raton, FL, June 2003.125. Goodman WK, et al. Escitalopram 10 mg each day is effective in the treatment of generalized anxiety disorder.American Psychiatric Association Institute on Psychiatric Services, Boston, MA, November 2003.126. Greenberg B, Friehs G, Malone D, Rezai A, Shapira NA, Foote K, Okun M, Rauch S, Dougherty D, Noren G,Updated 12/12/2009

Salloway S, Malloy P, Marsland R, Goodman W, Rasmussen S. Deep Brain Stimulation in Intractable OCD.American College of Neuropsychopharmacology (ACNP) Annual Meeting, San Juan, PR, December 2003.127. Murphy TK, Shapira NA, Bengtson MA, Soto-Raices O, Sajid M, Goodman WK. A Chart Review of the use ofAripiprazole in Children and Adolescents with Tic Disorders. ACNP Annual Meeting, San Juan, PR, December2003.128. Shapira NA, Murphy TK, Mann GD, Ward HE, Goodman WK. Effect of Comorbid Tics on Response to 8-WeekOpen-Label Trial of Fluoxetine in OCD. ACNP Annual Meeting, San Juan, PR, December 2003.129. Springer US, Bowers D, Shapira N, Goodman W, Greenberg B, Heilman K, Foote K, Okun MS. Long-termHabituation of Stimulation-induced Smile in a Patient with Deep Brain Stimulation. InternationalNeuropsychological Society Conference Annual Meeting, Baltimore, MD, February 2004.130. Goodman WK. Non-Pharmacological Devices in Treatment-Resistant OCD. Annual Anxiety Disorders Associationof America (ADAA) Conference, Miami, FL, March 2004.131. Goodman WK. Neurosurgery for Anxiety Disorders - An Introduction. Annual ADAA Conference, Miami, FL,March 2004.132. Wright P, Liu Y, He AH, Goodman WK. Distinct Neural Responses to Scenes Evoking Disgust, Fear and Horror.Annual ADAA Conference, Miami, FL, March 2004.133. Geffken GR, Storch EA, Gelfand K, Murphy T, Goodman W. Intensive cognitive behavior therapy for adults andchildren with Obsessive-Compulsive Disorder. Annual ADAA Conference, Miami, FL, March 2004.134. Goodman WK. The Anxiety Spectrum and its Emerging Treatments. Panel Discussion at NCDEU Annual Meeting,Phoenix, AZ, June 2004.135. Storch EA, Johns NB, Geffken GR, Soto O, Sajid M, Allen P, Roberti JW, Killiany EM, Goodman WK, MurphyTK. The Tourette’s Disorder Scale – Parent Rated Version: Further psychometric properties. International ScientificSymposium on Tourette’s Syndrome, Cleveland, OH, June 2004.136. Shapira A, Wint DP, Bowers D, Springer U, Fernandez HH, Goodman WK, Foote KD, Okun MS. Fear and PanicInduced by Deep Brain Stimulation, 18 th Annual Parkinson Study Group meeting, Toronto, Ontario, Canada,October 2004.137. Storch EA, Shapira NA, Ward H, Murphy T, Geffken G, Valerio H, Goodman WK. Clinical Predictors ofFluoxetine Treatment Response in Obsessive-Compulsive Disorder. American College ofNeuropsychopharmacology (ACNP) Annual Meeting, San Juan, PR, December 2004.138. Johns N, Storch E, Murphy T, Allen P, Roberti J, Geffken G, Goodman W. Reliability and validity of the Children’sYale-Brown Obsessive-Compulsive Scale. Annual Anxiety Disorders Association of America Conference, Seattle,WA, March 2005.139. Knight W, Shapira NA, Foote KD, Springer U, Goodman WK, Okun MS. Acute Blinded Stimulation of theAnterior Limb of the Internal Capsule and Nucleus Accumbens Region: Side Effects and Benefits. P507, PosterSession 3, International Movement Disorders Congress, New Orleans, LA, March 2005.140. Okun MS, Knight W, Shapira NA, Bowers D, Springer U, Martin P, Munson SK, Fernandez HH, Goodman WK,Foote KD, Benefits and Side Effects from Acute Blinded Stimulation of the Anterior Limb of the Internal Capsuleand Nucleus Accumbens Region, American Academy of Neurology, Miami, April 2005.141. Stein DJ, Andersen HF, Goodman WK. Escitalopram for the Treatment of GAD: Efficacy across DifferentSubgroups and Outcomes. American Psychiatric Association (APA) Annual Meeting, Atlanta, GA, May 2005.142. Liu Y, Goodman WK. DTI of Cerebellar and Basal Ganglia Pathways in OCD, American College ofNeuropsychopharmacology (ACNP) Annual Meeting, San Juan, PR, December 2005.143. Selke G, Mikos A, Springer U, Goodman W, Okun M, Bowers D. Enhanced startle modulation to contaminationpictures in Obsessive Compulsive Disorder: a case study. 34 th annual meeting of the International NeuropsychologySociety, Boston, MA, February 2006.144. Merlo LJ, Storch EA, Geffken GR, Adkins JW, Murphy TK, Goodman WK. Motivating patients and parents toengage in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. Anxiety Disorders Associationof America Annual Meeting, Miami, FL, March 2006.145. Storch EA, Murphy TK, Geffken GR, Duke D, Goodman WK. Cognitive-behavioral treatment for pediatricObsessive-compulsive disorder: Comparison of intensive versus weekly treatment. Anxiety Disorders Associationof America Annual Meeting, Miami, FL, March 2006.146. Goodman, WK. OCD Subtypes and Drug Treatment Response. Symposium #100, American PsychiatricAssociation (APA) Annual Meeting, Toronto, CA, May 25, 2006.Updated 12/12/2009

147. Okun MS, Bowers D, Foote KD, Rodriguez RL, Skidmore F, Goodman WK, Fernandez HH. Understanding HumanBasal Ganglia Limbic and Cognitive Functions Through Brain Stimulation. American Neurological Association,Chicago, IL, October 2006.148. Haq I, Foote KD, Goodman WG, Jacobson C, Okun MS. Neuroanatomical Locus of Subjective Panic-likePhenomenon in OCD DBS Subjects. 11th International Congress of Parkinson’s Disease and Movement Disorders.Istanbul, Turkey, June 2007.Invited Presentations:1. "Mechanisms of Action of Antidepressant Drugs." Connecticut Mental Health Center, Yale University, LustmanResearch Award Lecture, June 1986.2. "Treatment Approaches to Refractory Depression." Connecticut Mental Health Center, Yale University, LustmanResearch Award Lecture, June 1985.3. "New Research Approaches to Obsessive Compulsive Disorder." Biological Sciences Training Program Departmentof Psychiatry, Yale University School of Medicine, April 1986.4. "Obsessive Compulsive Disorder." Mental Health Association of Connecticut Symposium, Hartford, CT, September1986.5. "Instruction in the Use and the Administration of the Yale-Brown Obsessive Compulsive Scale." CIBA-GEIGYInvestigators' Meeting, Boston, MA, July 1986.6. "Instruction in the Administration of the Children's Yale-Brown Obsessive Compulsive Scale." CIBA-GEIGYInvestigators' Meeting, Toronto, Canada, October 1986.7. "Advances in the Understanding and Treatment of Obsessive Compulsive Disorder." Griffin Hospital, GrandRounds, Derby, CT, October 1986.8. "Biological Findings in Obsessive Compulsive Disorder." Mind-Brain Course, Yale psychiatric residents, WestHaven Veteran's Hospital, West Haven, CT, Dec 1986.9. "Serotonin Hypothesis of Obsessive Compulsive Disorder." University of Connecticut School of Medicine,Psychiatry Grand Rounds, Farmington, CT, March 1987.10. "Recent Advances in Obsessive Compulsive Disorder." Symposium Chairperson, 140th Annual Meeting AmericanPsychiatric Association, Chicago, IL., May 1987.11. "Biological Theories of Obsessive Compulsive Disorder." Meriden-Wallingford Hospital, Psychiatric GrandRounds, Meriden, CT, May 1987.12. "Update on Obsessive Compulsive Disorder." Hartford Hospital, Psychiatric Grand Rounds, Hartford, CT, May1987.13. "Psychopharmacological Treatment of OCD." Conference on Obsessions and Rituals: New Findings in Researchand Treatment at Butler Hospital, Brown University, October 1987.14. "Update on Pathogenesis and Treatment of OCD." Stamford Hospital, Grand Rounds, November 1987.15. "Neurobiology and Pharmacotherapy of Anxiety." Norwalk Hospital, Grand Rounds, January 1988.16. "The Role of the Basal Ganglia in OCD." Connecticut Mental Health Center, Grand Rounds, March 1988.17. "Overview of OCD." Fairfield Hills Hospital, Grand Rounds, Newtown, CT, April 1988.18. Symposium Co-Chairman, Obsessive Compulsive Disorder: An Overview. Symposium 47, APA, April 1988.19. "Ins and Outs of OCD" in OCD: Ruminations, Rituals and Recovery." Carrier Foundation, Belle Meade, NJ, May1988.20. "Treatment of OCD." Grand Rounds, Silver Hills Foundation, New Canaan, CT, Aug 1988.21. "Treatment Implications of Recent Findings in OCD." Grant Rounds, Yale Psychiatric Institute, New Haven, CT,September 1988.22. "Pharmacotherapy of OCD." Annual Meeting of the Connecticut Psychiatric Society, New Haven & MiddlesexCounty Chapter, New Haven, CT, October 1988.23. "Instruction in the Use of the Y-BOCS." Eli Lilly Investigators' Meeting, Indianapolis, Indiana, Oct 1988.24. "Update on OCD." Grand Rounds, St. Vincent's Hospital, Harrison, NY, Oct 1988.25. "Neurobiology/Drug Therapy of OCD" in Advances in Neurobiology and Treatment of Anxiety DisordersSymposium, Yale University School of Medicine, New Haven, CT, October 1988.26. "OCD: Treatment and Theory." Grand Rounds, Waterbury Hospital, Waterbury, CT, November 1988.27. "OCD as a Neurobiological Disorder." Panel Discussion, World Psychiatric Congress, New York City, November1988.28. "Biological Approaches to OCD." Grand Rounds, Hillside Hospital, Long Island, NY, December 1988.Updated 12/12/2009

29. "Neurobiological Theories of OCD, Grand rounds, New York University, Medical Center, New York, NY, April1989.30. "Neurobiological Findings of OCD," Symposium Chairman, Society for Biological Psychiatry Annual Meeting, SanFrancisco, California, May 1989.31. "Treatment of OCD." Grand Rounds, Hospital of St. Raphael, New Haven, CT, June 1989.32. "Predictors of Treatment Response and Relationship to TS", in the North American OCD Conference, Seattle,Washington, July 1989.33. "The Role of the New 5-HT Reuptake Inhibitors in OCD", in the symposium "Advances in OCD", Joint AnnualMeeting of the BAP/CCNP, Cambridge, England, July 1989.34. "Predictors of Treatment Response in Obsessive-Compulsive Disorder," in the symposium "Recent Advances inBipolar and OCD: Nature and Treatment, September 1989 (San Francisco) and December 1989 (Palm Desert, CA).35. "Implications of Drug Response in OCD." Grand Rounds, University of Connecticut Health Center, Farmington,CT, Oct 1989.36. "Biological Therapies of OCD." Grand Rounds, Institute of Living, Hartford, CT, Oct 1989.37. "Neurobiological Hypotheses of OCD," Grand Rounds, Department of Psychiatry, University of South Carolina,Charleston, SC., November 1989.38. "Recent Research Developments in OCD," Grand Rounds, Department of Psychiatry, University of Iowa, IowaCity, IO, December 1989.39. "Recent Advances in Understanding and Managing OCD," Grand Rounds, Department of Psychiatry, University ofTennessee, Memphis, March 1990.40. "Serotonergic Mechanisms in OCD," at "Obsessive Compulsive Disorder," a National Symposium sponsored byDuphar Laboratories Ltd., The Queen Elizabeth Conference Centre, Westminster, London, Friday, April 6, 1990.41. "Recent Advances in the Treatment of Obsessive-Compulsive Disorders," Grand Rounds, State University of NewYork at Syracuse, April 19, 1990.42. "The Neurochemical Basis of OCD," Psychiatry Grand Rounds, Brown University School of Medicine, Providence,RI, June 21, 1990.43. "New Neurochemical Theories of OCD," Payne-Whitney Grand Rounds, Cornell Medical School, New York, June28, 1990.44. "Serotonin Reuptake Inhibitors in OCD." Satellite Symposium of CINP, Kyoto, Japan, September, 1990.45. "Etiology & Differential Diagnosis of OCD." University of Miami, School of Medicine, September, 1990.46. "Obsessive Compulsive Disorder." Waterbury Hospital, Department of Psychiatry Grand Rounds, October, 1990.47. "Understanding Obsessive Compulsive Disorder." Connecticut Alliance for the Mentally IL, Charlotte HungerfordHospital, Torrington, CT, October 11, 1990.48. "Assessment of OCD." Tucson Workshop on OCD, Tucson, AZ, October, 1990.49. "Update on Treatment of OCD." Danbury Hospital, Grand Rounds, Danbury, CT, Nov 1990.50. "Instruction in Y-BOCS." Philadelphia Investigators' Meeting, November 1990.51. "Neurobiology of OCD." Medical College of Georgia, Department of Psychiatry, Grand Rounds, February 1991.52. "Assessment of OCD." Japanese Psychiatric Society, Kyoto and Osaka, Japan, February 1991.53. "Diagnosis and Treatment of OCD." Grand Rounds, Department of Psychiatry, Massachusetts General Hospital,Boston, Mass., March 1991.54. "Overview of OCD." OCD Self-Help Group of Upstate NY, Binghamton, NY, April 1991.55. "Assessment of OCD." Multinational OCD Investigators' Meeting, Brussels, Bel, May 1991.56. "Diagnosis of Obsessive-Compulsive Disorder," College of Physicians & Surgeons of Columbia University,Department of Psychiatry, New Directions in the Diagnosis, Biology & Treatment of Obsessive-CompulsiveDisorder, New York City, June 1, 1991.57. "Drug Therapy and Other Somatic Treatments in the Treatment of Obsessive-Compulsive Disorder," McLeanHospital, Belmont Massachusetts, June 14, 1991.58. "Obsessive Compulsive Disorder: Diagnosis and Treatment," Grand Rounds, Department of Psychiatry, Universityof Cincinnati, June 19, 1991.59. "Treatment of OCD," US OCD Update, Denver, Colorado, August 1991.60. "Comorbidity of OCD," Freud Art Museum Tour, Houston, Texas, August 1991.61. "Pharmacotherapy of OCD," 4th International Symposium on Impulsive Drives, Amsterdam, The Netherlands,September 1991.62. "New Theories of OCD," Department of Psychiatry, Grand Rounds, US Naval Medical Center, Bethesda, MD,Updated 12/12/2009

September 1991.63. "Approaches to Treatment Resistant OCD," Brown University School of Medicine Symposium on OCD, September1991.64. "Serotonin Reuptake Inhibitors in OCD," European College of Neuro-Psychopharmacology Annual Meeting inMonte Carlo, Monaco, October 199165. "Theory and Treatment of OCD," Co-Chairman of symposium at the University of Hamburg, Hamburg, Germany,October 1991.66. "Approaches to Treatment-Resistant OCD," Grand Rounds, Dept of Psychiatry, University of Wisconsin, October1991.67. "Advances in the Treatment of OCD", Grand Rounds, Dept of Psychiatry, Boston University School of Medicine,April 1992.68. "Biological Approaches to Treatment-Resistant OCD," Annual Meeting of the American Psychiatric Association,May 1992.69. "Multicenter Trial of Fluvoxamine in OCD," Annual Meeting of NCDEU, Boca Raton, FL, May 1992.70. "Pharmacotherapy of OCD", Grand Rounds, Dept of Psychiatry, University of Toronto, Toronto, Canada, June1992.71. "Efficacy of Fluvoxamine in OCD," CINP Meeting, Nice, France, June 1992.72. "The Treatment of OCD with SRIs," Symposium on Obsessive Compulsive Disorders, 2nd InternationalSymposium on Serotonin from Cell Biology to Pharmacology and Therapeutics, Houston, TX, September, 17,1992.73. "Obsessive-Compulsive Disorder Drug Treatment," Conference on New Insights in the Treatment of Obsessive-Compulsive Disorder, Columbia University College of Physicians and Surgeons, New York, NY, October 3, 1992.74. "Treatment of OCD in the Primary Care Setting," West Virginia University School of Medicine, Morgantown, WestVirginia, October 1992.75. "Approaches to Treatment-Resistant OCD," in Columbia University, College of Physicians and SurgeonsConference on the Treatment of OCD, NYC, Oct 1992.76. "Approaches to Treatment-Resistant OCD," in Course, "Obsessive-Compulsive and Related Disorders: Challengesand Novel Strategies," Dept of Psychiatry, University of Miami School of Medicine and So Florida PsychiatricSociety, Inc., Coral Gables, FL, Dec 5, 1992.77. "Role of Serotonin in OCD," in Serotonin Symposium sponsored by Marion-Merrell Dow, Inc., Hawaii, January1993.78. "Design of Clinical Trials in OCD," presented before the Belgium meeting of psychiatry department chairpersons,Brussels, January 1993.79. "Treatment and Research of Adolescent OCD," presented at Psychiatry Grand Rounds in Adolescent Psychiatry,Baystate Medical Center, Springfield, MA, January 28, 1993.80. "Support for the role of serotonin in OCD," Grand Rounds, Medical College of Pennsylvania, February 1993.81. "Assessment and Treatment of OCD", OCD symposium at the Laureate Clinic, Tulsa, Oklahoma, February 1993.82. "The Neurobiology of OCD," symposium sponsored by the University of Texas, Southwestern Medical Center atDallas, April 1993.83. "Serotonin Hypothesis of OCD," Annual Meeting of the West Virginia Chapter of the Society for Neuroscience,Morgantown, West Virginia, April 1993.84. "Pharmacotherapy of OCD: Implications for Pathophysiology," Psychiatry Grand Rounds, Ohio State University,Columbus, Ohio, May 1993.85. "Advances in the Understanding and Treatment of OCD", Psychiatry Grand Rounds, Northeastern OhioUniversities College of Medicine, Akron, Ohio, Dec 1993.86. "Serotonin Reuptake Inhibitors in the Treatment of OCD", Jacksonville Psychiatric Society, Jacksonville, Florida,February 1994.87. "Annual Review of Psychopharmacology ", New York University School of Medicine, New York, NY, March1994.88. "Advances in Psychopharmacology of OCD" Psychiatry Grand Rounds, University of South Florida, Tampa,Florida, March 1994.89. "Approaches to Treatment-Resistant OCD ", Tampa Psychiatric Society, Tampa, Florida, March 1994.90. "Pharmacological Approaches to the Treatment of OCD", Grand Rounds, Department of Clinical & HealthPsychology, University of Florida, April 15, 1994.Updated 12/12/2009

91. "Practical pharmacology of OCD", North Central Florida Psychiatric Association, Ocala, Florida, May 5, 1994.92. "Serotonin hypothesis of OCD revisited" Hennepin County Medical Center, Grand Rounds, May 6, 1994.93. "OCD and TS: Two sides of the same coin", Tourette Syndrome Association, University of Florida, Gainesville,Florida, June 11, 1994.94. "Biological Approaches to the Treatment of OCD", Grand Rounds, Dept of Psychiatry, Rush-Presbyterian-St.Luke's Medical Center, Chicago, Illinois, June 22, 1994.95. "OCD and Comorbid Conditions", XIXth CINP Congress, Washington, DC, June 28, 1994.96. "Medications for OCD and the End of the Millennium", XIXth CINP Congress, Washington, DC, June 28, 1994.97. "How do SRIs Really Work in OCD", XIXth CINP Congress, Washington, DC, June 29, 1994.98. "British Association for Psychopharmacology and Interdisciplinary of Biological Psychiatry", 1994 Joint Meeting:Cambridge, UK, July 10-13, 1994.99. "Obsessive Compulsive Disorder", Southwestern Medical School Meeting, Zale Lipshy Hospital, August 18, 1994.100. "Approaches Treatment Resistant OCD", Oschner Clinic, New Orleans, LA, September 1, 1994.101. "Approaches to the Treatment Resistant OCD", LSU Grand Rounds, Shreveport, LA, September 16, 1994.102. "Diagnosis and Treatment of OCD", Emory University, Atlanta, Georgia, September 24, 1994.103. "Advances in the Understanding and Treatment of Obsessive Compulsive Disorder", Grand Rounds, University ofUtah, Salt Lake City, Utah, October 4, 1994.104. "Treatment of OCD Patients and the interface with Tourette's Syndrome", (First Heath Lecture) Tulane UniversityMedical Center, New Orleans, Louisiana, October 15, 1994.105. "Obsessive Compulsive Disorder", Grand Rounds, Medical University of South Carolina, Department ofPsychiatry, Charleston, South Carolina, October 25, 1994.106. "Diagnosis and Treatment of OCD", Grand Rounds, University of Alabama School of Medicine, Birmingham,Alabama, October 28, 1994.107. "Update on Pharmacologic Treatment of Obsessive Compulsive Disorder", Grand Rounds, Wayne State University,Department of Psychiatry, Detroit, Michigan, December 7, 1994.108. "Obsessive Compulsive Disorder", Stanford Symposium, Stanford, CA, January 21, 1995.109. "Recent Advances in OCD", Grand Rounds, Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio,February 1, 1995.110. "Update on Obsessive Compulsive Disorder," Grand Rounds, Scott White Clinic, Austin, Texas, February 24, 1995.111. "Update on pharmacologic treatment of OCD," 9th Annual Symposium of Psychiatric Medicine, Florida HospitalSymposium, Orlando, Florida, March 20, 1995.112. "Pharmacological Treatment of OCD," Grand Rounds, Department of Psychiatry, University of Texas, Galveston,Texas, April 11, 1995.113. "Approaches to Treatment-Resistant OCD," Grand Rounds, Department of Psychiatry, University of Chicago,Chicago, Illinois, April 17, 1995.114. "Advances in Treatment of OCD," Keynote Address, The Clarke Institute of Psychiatry, Mood & Anxiety DisordersDivision, Toronto, May 27, 1995.115. "Treatment of OCD," NCDEU, Orlando, Florida, June 2, 1995.116. "Psychopharmacological Treatment of Anxiety Disorders," 48th Annual Convention, Florida PsychologicalAssociation, Key West, Florida, June 17, 1995.117. “Anxiety Disorders in the Primary Care Setting”, Halifax Medical Center, Sept. 8, 1995118. “Advances in OCD Research”, Grand Rounds, University of Michigan, Ann Arbor, MI, September 20, 1995.119. “Overview of Obsessive Compulsive Disorder”, Southern Medical Association, Sea Island, Georgia, October 18-20,1995.120. Chairman, Symposium on Treatment-Refractory OCD sponsored jointly by NIMH and OCF, New Hampshire,October 23-25, 1995.121. “Biological Approaches to OCD”, Grand Rounds, East Carolina University, Greenville, North Carolina, December6, 1995.122. “Clinical Advances in OCD”, Grand Rounds, Hall Psychiatric Institute, Columbia, South Carolina, January 18,1996.123. “Obsessive Compulsive Disorder: overview and treatment”, 7th Annual Osteopathic Winter Seminar, Pinellas Park,Florida, January 25, 1996.124. “Treatment of Obsessive Compulsive Disorder”, Grand Rounds, Cleveland Clinic, Ohio, February 8, 1996.125. Workshop Chair, 2nd International OCD Conference, Guadaloupe, TX February 16-17, 1996.Updated 12/12/2009

126. “Advances in Treatment and Neurobiology of OCD”, Grand Rounds, Duke University, February 22, 1996.127. “Recent Advances in OCD”, Grand Rounds, Douglas Hospital, Montreal, Canada, March 20, 1996.128. “Pharmacological Management of OCD”, Symposium on OC and Spectrum Disorders, Atlanta, GA April 13,1996.129. “Treatment of OCD”, American College of Obstetrics and Gynecology, Denver, Colorado, April 29-30, 1996.130. “Obsessive Compulsive Disorder: Treatment Update”, Ohio State University, Columbus, Ohio, April 27, 1996.131. “Neurobiology of OCD”, American Psychiatric Association Meeting, New York, May 1996.132. “Sydenham’s Chorea, Childhood OCD, and TS: 3 sides of the same coin?” University of Alabama, Birmingham,AL , September 5, 1996.133. “Pharmacotherapy of OCD,” Buffalo Psychiatric Center, University of Buffalo, New York, October 1996.134. “Assessment of OCD,” Contemporary issues in mood and anxiety disorders, Atlanta, Georgia October, 1996.135. “Treatment of OC-spectrum disorders,” US Naval Air Station, Jacksonville, Florida , November 1996.136. “Neurobiology and treatment of OCD”, Yale University, January 1997.137. “Pharmacotherapy of OCD”, Nevada Association of Psychiatric Physicians’ conference, Las Vegas Nevada,February 1997.138. “OCD and related disorders”, Psychiatric Grand Rounds, East Tennessee State University, Johnson City, TennesseeMarch 1997139. “OCD, TS, and Sydenham’s Chorea: 3 sides of the same coin?”, Neuropsychiatric Grand Rounds, TulaneUniversity, New Orleans, LA, March 1997140. “Neuropsychiatric Symptoms of Sydenham’s Chorea”, Pediatrics Grand Rounds, University of Florida Jacksonville,May 1997.141. “Future Directions in Research”, Keynote Address, Annual OCF Meeting, Orlando, Florida, August 1997.142. “Autoimmune Mechanisms in OCD”, University of Sao Paulo, Brazil. August 1997.143. “Recent advances in OCD”, St-Sauveur, Quebec, September 1997.144. “Relationship between Sydenham’s Chorea and OCD”, International OCD Council Meeting, Pisa, Italy, September1997.145. “Treatment of OC behavior in TS”, International Symposium on TS, Quebec City, Canada, October 1997.146. "Mixed 5HT-NE Uptake Inhibition in Depression." Wyeth-Ayerst Visiting Professor Program, Tallahassee, Florida,February 1998.147. "Neuropsychiatric Aspects of Sydenham's Chorea." Central Florida Psychiatric Society Meeting, Orlando, Florida,March 1998.148. "Relationship between OCD and TS." Northwest Florida Psychiatric Association Meeting, Pensacola, Florida, April1998.149. "Pathogenesis, Physiopathology and the Role of Serotonin in OCD." Pfizer OCD Symposium; Quito, Ecuador,Bogota and Medellin, Columbia, and Caracas, Venezuela; June 1998.150. "Diagnosis, Y-BOCS Scale, New Approaches in Treatment and Use of SSRIs, Mainly Sertraline." Pfizer OCDSymposium; Quito, Ecuador, Bogota and Medellin, Columbia, and Caracas, Venezuela; June 1998.151. “Pandas and OCD”, Duval County Mental Health, Jacksonville, FL, August 1998.152. “Pramipexole in the treatment of major depression”, In Symposium of Issues, Options and Opportunities withDopamine Agonists, 3 rd Congress of the European Federation of Neurological Societies, Seville, Spain, September1998.153. “Frontal Lobes and OCD”, 24 th Annual Course in Behavioral Neurology and Neuro-psychology, Orlando, Florida.December 1998.154. “Tourette’s Syndrome.” Ask on Family Doctor, America’s Health Network, Orlando, Florida, February 24, 1999.155. "Training for the Y-BOCS." Solvay Investigator's Meeting, Atlanta, GA, Feb 25, 1999.156. "Can Strep Throat Cause Tics?" Quarterly Meeting of Florida Tourette's Association, Gainesville, Florida, May 8,1999.157. “New Research Developments in OCD .” St. Joseph’s Hospital Presentation, Tampa, Florida, June 16, 1999.158. "Treatment of Refractory/Co-morbid OCD." Program on Treatment of the Complicated Psychiatric Patient, TulaneUniversity School of Medicine, New Orleans, Louisiana, June 26, 1999.159. "Symposium on OCD and Treatment Strategies." The Obsessive-Compulsive Foundation Annual Conference,Arlington, Virginia, July 9-11, 1999.160. "Symposium on OCD and Medications." The Obsessive-Compulsive Foundation Annual Conference, Arlington,Virginia, July 9-11, 1999.Updated 12/12/2009

161. “The Role of Norepinephrine in Managing Depression.” Pinellas County Psychiatric Society Meeting, St.Petersburg, Florida, August 26, 1999.162. “Biological Treatment of OCD and Related Disorders.” University of Florida Southeastern Psychiatric TreatmentUpdate, St. Augustine, Florida, August 28, 1999.163. “Anxiety and OCD.” University of Mississippi Psychopharmacology Update, Jackson, Mississippi, October 9,1999.164. “Autoimmune Mechanisms in CNS Illness.” American College of Neuropharmacology 38 th Annual Meeting,Acapulco, Mexico, December 12-16, 1999.165. "Shrink Rap: New Windows into Mental Illness"; 7 th Annual Mini-Medical School: Health Discoveries 2000,University of Florida Brain Institute, Gainesville, Florida, March 15, 2000.166. "Advances in Treatment Resistant Anxious Depression"; Jacksonville Psychiatric Society, Jacksonville, Florida,April 25, 2000.167. "Pharmacological Approaches to Treatment Refractory OCD", Psychiatric Grand Rounds, University ofPennsylvania Health System, Philadelphia, Pennsylvania., May 25, 2000.168. "Approaches to Treatment Resistant OCD"; Psychiatric Grand Rounds, Evanston Hospital, Evanston, Illinois, June13, 2000.169. “Drug Therapy of OCD: SRIs and Beyond.” Milestones at the Millennium Symposium at the Annual Meeting of theAnxiety Disorders Association of America, Washington, DC, March 24-26, 2000.170. "Achieving Remission in GAD", College of Psychiatric and Neurologic Pharmacists, San Antonio, Texas, March27, 2001.171. “The Diagnosis and Measurement of OCD in Children”, Tokyo, Japan, June 3, 2001.172. “Advances in Medication Augmentation and Deep Brain Stimulation”, The 2001 OCF Scientific Advisory BoardAnnual Meeting, Denver, Colorado, July 20-22, 2001.173. “Anxiety Disorders: Generalized Anxiety Disorder”, Psychopharmacology update, Ohio State University,Columbus, Ohio, April 13, 2002.174. “Anxiety Disorders: OCD”, Psychopharmacology update, Ohio State University, Columbus, Ohio, April 13, 2002.175. “Limited Efficacy of Current Treatment for Obsessive Compulsive Disorder” Wyeth-Ayerst Research Meeting,Monmouth Junction, New Jersey, April 17, 2002.176. “Research Strategies for the Study of Nonpharmacological Biological Treatments”, NCDEU Annual Meeting, BocaRaton, Florida, June 10, 2002.177. “Beyond Medication: Surgery and Deep Brain Stimulation” OCF Annual Meeting, Philadelphia, Pennsylvania,August 9, 2002.178. “Sertraline Antidepressant Heart Attack Trial (SADHaRT)” Pfizer RMRS Central Nervous System/CardiovascularCross Talk Program, Tampa, Florida, November 25, 2002.179. “Update on Deep Brain Stimulation” Keynote Speaker, TSA Scientific Advisory Meeting, Atlanta, Georgia,February 1, 2003.180. “Selecting Treatments for Generalized Anxiety Disorder” Generalized Anxiety Disorder Roundtable: The Specifics,San Diego, California, February 6, 2003.181. “Treatment of Obsessive Compulsive Disorder” Anxiety & Depression Update 2003, Ponte Vedra Beach, Florida,February 15, 2003.182. “Treatment of OCD” Video Conference for Yale University Department of Psychiatry, March 17, 2003.183. “New Treatment Approaches to Obsessive-Compulsive Disorder” Grand Rounds, Medical College of Georgia,Augusta, Georgia, May 15, 2003184. “Depression” Noon Conference, Department of Community Health & Family Medicine, UF/Shands at AGH FamilyPractice Residency Program, Gainesville, Florida, June 25, 2003.185. “Biology and Treatment of Obsessive Compulsive Disorder”, Current Concepts in Neuro-sciences and Psychiatry:Fall Symposium, Department of Neuropsychiatry and Behavioral Science, University of South Carolina School ofMedicine, Greenville, South Carolina, September 20, 2003.186. “Biological, Non-Pharmacological Treatment of Refractory OCD”, Florida Psychiatric Society 2003 Fall Meeting,Ponte Vedra Beach, Florida, October 4, 2003.187. “Psychopharmacology for Complicated Anxiety Disorders”, Psychopharmacology Update 2003, Department ofPsychiatry & Behavioral Science, Baylor College of Medicine, Houston, Texas, October 19, 2003.188. “OCD - Moving the Field Forward”, International OCD Conference, Lanzarote, Canary Islands, Spain, November14, 2003.Updated 12/12/2009

189. “Biological Devices in the Treatment of OCD”, Psychiatry Grand Round, Vanderbilt University Medical Center,Nashville, Tennessee, January 27, 2004.190. “Non-Pharmacological Devices in Treatment-Resistant OCD”, Annual Anxiety Disorders Association of AmericaConference, Miami, Florida, March 2004.191. “Neurosurgery for Anxiety Disorders – An Introduction”, Annual Anxiety Disorders Association of AmericaConference, Miami, Florida, March 2004.192. "Neurosurgical interventions in OCD", Mood and Anxiety Disorders Conference, Los Angeles, California, April 17,2004.193. “OCD and related disorders: Pharmacology in Adults and Children”, CME Conference: Moods & AnxietyDisorders: Current Clinical Management, Marina Del Rey, California, April 17, 2004.194. “Deep Brain Stimulation for Treatment-Resistant OCD”, Obsessive-Compulsive Foundation Annual Conference,July 2004.195. “Anxiety”, Psychopharmacology Academy Two-Day Symposia presented by the Neuroscience Education Institute,New York, New York, September 18-19, 2004.196. “The FDA Process and Thoughts on the Neurobiology of Activation Syndromes”, AACAP Research Forum: Issuesin the Conduct and Interpretation of Intervention Studies of Adolescent Depression, Washington, DC, October 20,2004.197. “Deep Brain Stimulation in OCD”, Grand Rounds, Indiana University Department of Psychiatry, Indianapolis,Indiana, October 29, 2004.198. “Generalized Anxiety Disorder: Overview and Pharmacotherapy”, Psychopharmacology Update for Primary Careand Psychiatry, Gainesville, Florida, November 6, 2004.199. “Use of Antidepressants in Children”, Pediatric Faculty Presentation, University of Florida College of Medicine,Gainesville, Florida, December 1, 2004.200. “FDA Advisory Committee Perspective”, Psychiatry Grand Rounds, University of Florida College of Medicine,Gainesville, Florida, December 10, 2004.201. "FDA Hearings on Antidepressant Use in Children", Florida Expect Colloquium, Tampa, Florida. January 21, 2005.202. “Use of Antidepressants in Children”, Psychopharmacology Update for Primary Care and Psychiatry, University ofFlorida, Gainesville, Florida, March 9, 2005.203. “Suicidality Associated with Antidepressants in Children”, Grand Rounds, University of Florida Department ofPediatrics, Jacksonville, Florida, May 11, 2005.204. “Clinical Update on Obsessive Compulsive Disorder”, Student Health Care Center Educational Series, University ofFlorida, Gainesville, Florida, August 31, 2005.205. “Approaches to Treatment-Resistant Obsessive Compulsive Disorder”, Grand Rounds, University of North CarolinaDepartment of Psychiatry, Chapel Hill, North Carolina, September 9, 2005.206. “Controversies in the Use of Antidepressants”, Grand Rounds, East Tennessee State University, Department ofPsychiatry, Johnson City, Tennessee, September 16, 2005.207. “Obsessive-Compulsive Disorder in TS”, Neurobiology of Disease in Children Symposium at the 34 th Annual ChildNeurology Society Meeting, Los Angeles, California, September 28, 2005.208. “VNS Therapy: A Long-term Strategy for Treatment Resistant Depression.” Chair, Cyberonics RegionalSymposium, Orlando, Florida, October 1, 2005.209. “Deep Brain Stimulation in Intractable OCD.” Ground Rounds, Washington University Department of Psychiatry,St. Louis, Missouri, October 11, 2005.210. “Deep Brain Stimulation in Psychiatric Disorders.” Scripps Florida:The Scripps Research Institute, Jupiter, Florida,January 19, 2006.211. “DBS in Treatment Resistant OCD.” Ground Rounds, University of Pennsylvania, Philadelphia, Pennsylvania,January 26, 2006.212. “Deep Brain Stimulation in OCD.” Ground Rounds, Mt. Sinai School of Medicine, New York City, New York,February 7, 2006.213. “Deep Brain Stimulation and Other Novel Treatments for OCD.” Ground Rounds, New York University,Department of Psychiatry, School of Medicine, New York City, New York, March 9, 2006.214. “Safe Use of Antidepressants in the Pediatric Population,” Florida Expert Panel on the Best Practices for the use ofPsychiatric Medications in Children and Adolescents, Tampa, Florida, June 10, 2006.215. “Deep Brain Stimulation in OCD.” Ground Rounds, University of Texas Medical Branch, Department of Psychiatryand Behavioral Sciences, Galveston, Texas, November 28, 2006.Updated 12/12/2009

216. "Keeping OCD in the Anxiety Disorders." Session: Obsessive-Compulsive Disorder: To Stay or Not To Stay?Satellite Scientific Research Symposium, Anxiety Disorders Association of America, St. Louis, Michigan, March29th, 2007.217. “Translating Neuroscience Discoveries into New and Better Psychiatric Treatments”, Alliance for Research WinterMeeting, February 8, 2008, Rockville, Maryland.218. “Treatment Innovations through Translational Research.” Conference on Critical Research Issues in Latino MentalHealth, Santa Fe, New Mexico, March 10, 2008.219. “T1 Translational Research”, Association of Academic Chairs of Psychiatry, Washington, D.C., May 2008.220. ”Brain Pacemakers: A promising Approach and a New Era of Hope for NeurologicalDisorders.” US Department of Health and Human Services. Washington, DC May 6 th 2008.221. “Advancing Treatment through Translational Research”, Keynote Presentation, Trichotillomania Learning CenterInc, Chicago, Illinois, April 26-27, 2008.222. ”Beyond the ECT: The Challenges of New Somatic Research” New Research Approaches for Mental HealthInterventions (NCDEU) Phoenix, Arizona Tuesday May 27, 2008.223. ”Enhancing Signal detection in Depression Clinical Trials: Focus on Early Research”. Co-Chair; Discussant,Phoenix, Arizona Wednesday, May 28, 2008.224. “Research Advances in OCD,” 15 Annual OCF Conference, Keynote Speaker, Obsessive Compulsive Foundation.Boston, Massachusetts, July 31-August 3 rd .225. “NIMH Strategic Plan: Implications for Researchers”, McLean Hospital, Harvard University, Belmont, MA, Oct 21,2008226 “NIMH Strategic Plan: Implications for Researchers”, Department of Psychiatry Grand Rounds, Mount SinaiSchool of Medicine, New York, NY, Nov 4, 2008.227 “NIMH Strategic Plan: Implications for Researchers”, Department of Psychiatry Grand Rounds, University ofMassachusetts, Worcester, MA, Dec 17, 2008.228 “NIMH Funding of Research Training”, Research Colloquium for Junior Investigators, San Francisco, CA. May 17,2009229 “Neurosurgery for Severe OCD,” 16 th Annual OCF Conference, Minneapolis, MN. August 7, 2009.230 “Approaches to Translational Research in Mental Disorders,” Grand Rounds, Brown University, Department ofPsychiatry, Providence, RI, November 4 th , 2009.Meetings Organized at NIMH:1. "Integrating Biomarkers into Clinical Trials." Neuroscience Center, Rockville, MD, September 2008.2. “New Perspectives in the Translational Neuroscience of Late-Life Mental Disorders.” Hyatt Regency, Bethesda,MD. February 2009GRANTS AND CONTRACTS:1. Federal Grants:a. NIMH "DSM-IV Field Trial of OCD". PI: Edna Foa, PhD; Co-Investigator: WK Goodman, MD, 1991b. MH-86-18: NIMH Extramural Research Support Programs: "Neurobiology of Tourette's Syndrome and RelatedDisorders." PI: James F. Leckman, MD; Co-investigator: WK Goodman, MD, 8/89-7/92c. NIMH Program Project "Pathogenesis and Treatment of TS, OCD, and Related Childhood-Onset Disorders".PI: James F. Leckman, MD; Co-Investigator: WK Goodman, MD, 9/92-8/95d. NIMH R01 MH37757 "Fear and the Anxiety Disorders: Brain and Behavior.” PI: Peter J. Lang, PhD; Co-Investigator: WK Goodman, MD, 7/94-4/02.e. R24-MH51846 “Florida Neuropsychiatric Research Infrastructure Program (RISP).” PI: Dwight L. Evans, MD;Co-Investigator: WK Goodman, MD, 4/95 to 3/00f. NIMH R01 MH55454 “HIV in Women: Stress, Immunity, and Disease Progression." PI: Dwight L. Evans,MD; Co-Investigator: WK Goodman, MD, 9/97-4/01 .g. NIMH R01 MH56597 “Antigen D8/17 as a marker for childhood onset OCD/TS?” PI: WK Goodman, MD.3/97-2/01 ($614,720)h. NIMH R01 MH45802 "Neurobiology and Treatment of Obsessive Compulsive Disorder". PI: WK Goodman,MD. 9/92-8/97 ($506,761); 4/97-3/01 ($510,916)Updated 12/12/2009

i. NINDS R13 NS40925 “Neurobiology of Disease in Children Conferences”. PI: Bernard L. Maria, MD, MBA;Co-Director, Tourette Syndrome Conference: WK Goodman, MD, 04/01–03/06j. NIMH R21 MH64161 Exploratory/Development Grants for MH Intervention Research, “Pilot Study of DBS forTreatment-Refractory OCD”, PI: WK Goodman, MD, 8/02-7/06 ($765,987). Supplement 2006-2007 ($52,000).k. NIMH R01 MH063914 “Prospective Study of PANDAS”. PI: WK Goodman, MD. 4/02-3/07 ($2,733,826) (PIturned over to Tanya Murphy)l. NIMH R01 MH078594, “SSRI-Induced Activation Syndrome In Pediatric OCD”, PI: WK Goodman, MD,8/06-7/10 ($1,252,576) (PI turned over to Tanya Murphy)m. NIMH R01 subcontract, “Controlled Trial of DBS for OCD”. PI: Benjamin Greenberg, MD, PhD; Site PI: WKGoodman, 8/06-7/11 ($862,467); (Site PI turned over to Tanya Murphy)2. Mentored Grants:a. Monoclonal D8/17 Positivity: A Peripheral Marker for Some Forms of OCD. Obsessive CompulsiveFoundation Research Grant. PI: Tanya K. Murphy, MDb. Schizophrenia and Obsessive Compulsive Symptoms: Comorbidity and Treatment Implications. NARSAD YoungInvestigator Award. PI: Matthew Byerly, MDc. Schizophrenia and Obsessive Compulsive Symptoms: Comorbidity and Treatment Implications. University ofFlorida DSR Research Development Award. PI: Matthew J. Byerly, MDd. A Double-Blind Placebo-Controlled Trial of Tramadol Hydrochloride in Outpatients with Treatment-RefractoryObsessive-Compulsive Disorder. NARSAD Young Investigator Award. PI: Nathan A. Shapira, MD, PhDe. A Double-Blind Placebo-Controlled Trial of Tramadol Hydrochloride in Outpatients with Treatment-RefractoryObsessive-Compulsive Disorder. Obsessive Compulsive Foundation Research Grant. PI: Nathan A. Shapira,MD, PhDf. Neuroimmunology of Childhood Psychiatric Disorders. Mentored Patient-Oriented Research CareerDevelopment Award (K-23). PI: Tanya K. Murphy, MDg. Dynamic fMRI Analysis of the Brain Circuits Mediating Treatment Refractory Obsessive-CompulsiveDisorder. 2001 NARSAD Young Investigator Award. PI: Yijun Liu, PhDh. A Randomized Double-Blind Comparison Crossover Trial of Tramadol Hydrochloride vs. Risperidone inOutpatients with Tourette’s Syndrome. 2001 NARSAD Young Investigator Award. PI: Nathan A. Shapira, MD,PhDi. Measure of Cellular Activation Markers in Children with OCD and Tic Exacer-bations. 2002 NARSAD YoungInvestigator Award. PI: Tanya K. Murphy, MD.j. Characterization of Lymphocytic Diversity in Children with Tic Exacerbations. 2002 Tourette SyndromeAssociation Research Award. PI: Tanya K. Murphy, MD.k. Potential Role of Human Parvoviruses in the Etiology of Schizophrenia. Stanley Medical Research InstituteGrant, 2004-05. PI: Jacqueline A. Hobbs, MD, PhD3. Pharmaceutical Industry:Yale Universitya. Efficacy of Anafranil in the Treatment of Obsessive Compulsive Disorder (CIBA-GEIGY). PI: WK Goodman,MDb. Psychometric Study of the Yale-Brown Obsessive Compulsive Scale (CIBA-GEIGY). PI: WK Goodman, MDc. Efficacy of Fluvoxamine in the Treatment of Obsessive Compulsive Disorder (Reid-Rowell). PI: WKGoodman, MDd. Efficacy of Fluoxetine in the Treatment of Obsessive Compulsive Disorder (Lilly). PI: WK Goodman, MDe. Efficacy of Sertraline in the Treatment of Obsessive Compulsive Disorder (Pfizer). PI: WK Goodman, MDf. Open Trial of Nefazodone in Obsessive Compulsive Disorder (Bristol Myers). PI: WK Goodman, MDg. Efficacy of Gepirone in Obsessive Compulsive Disorder (Bristol Myers). PI: WK Goodman, MDh. Dose Ascendancy Study of Clomipramine (CIBA-GEIGY). PI: WK Goodman, MDi. Efficacy of Paroxetine in OCD (SmithKline-Beecham). PI: WK Goodman, MDj. Efficacy of Odansetron in Social Phobia (Glaxo Pharmaceuticals). PI: WK Goodman, MDUpdated 12/12/2009

k. Open-Label Trial of Clozapine in Treatment-Resistant OCD (Sandoz Pharmaceuticals). PI: Linda C. Barr, MD;Co-PI: WK Goodman, MDl. Comparative Efficacy of Sertraline vs. Desipramine in Patients with Concurrent OCD and Major Depression(Pfizer Pharmaceuticals) PI: WK Goodman, MDUniversity of Floridaa. Sertraline Treatment Followed by a Double-Blind Comparison of Sertraline and Placebo in the Prevention ofRelapse in Outpatients with OCD (Pfizer Pharmaceuticals). PI: WK Goodman, MDb. Double-Blind Flexible Dose Parallel Comparison of Sertraline and Placebo in Outpatients with Panic Disorder(Pfizer). PI: WK Goodman, MDc. Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in the Acute Exacerbation ofSchizophrenia/Schizoaffective Disorder (Pfizer). PI: Matthew J. Byerly, MD; Co-PI: WK Goodman, MDd. Flesinoxan in the treatment of generalized anxiety disorder: A Placebo-Controlled Comparison with Buspironein Outpatients (Solvay Pharmaceuticals). PI: WK Goodman, MDe. Adjunctive Pindolol in Fluoxetine Treated Patients with Obsessive Compulsive Disorder (Eli Lilly & Co.). PI:WK Goodman, MDf. Fluoxetine vs. Placebo in OCD Relapse Prevention (Eli Lilly). PI: WK Goodman, MDg. Fluvoxamine: Relapse Prevention Study in the Maintenance Treatment of Outpatients with Obsessive-Compulsive Disorder (Solvay Pharmaceuticals). PI: WK Goodman, MDh. Flexible Dose Study of Sertraline in the Treatment of Post-Traumatic Stress Disorder. (Pfizer). PI: WKGoodman, MDi. Risperidone vs. Haloperidol for Prevention of Relapse in Schizophrenia and Schizoaffective Disorders (JanssenResearch Found). PI: WK Goodman, MDj. Venlafaxine-ER in the Prevention of Relapse in Major Depression (Wyeth-Ayerst Research). PI: WKGoodman, MDk. Venlafaxine, Fluoxetine or placebo in Geriatric Outpatients with Major Depression (Wyeth-AyerstLaboratories). PI: WK Goodman, MDl. U-101387: Double-blind, Haloperidol-controlled, Safety and Dose-finding Study in the Treatment ofSchizophrenia (Pharmacia & Upjohn). PI: WK Goodman, MDm. Placebo Controlled Trial to Compare the Clinical Effects of Immediate Release Paroxetine and ModifiedRelease Paroxetine in the Treatment of Major Depression (SmithKline Beecham). PI: WK Goodman, MDn. Computer-Assisted versus Clinician-Administered Behavior Therapy for Obsessive Compulsive Disorder: AMulticenter, Randomized, Controlled Trial (Pfizer). PI: WK Goodman, MDo. Paroxetine vs. placebo in Children and Adolescents with OCD (SmithKline Beecham). PI: WK Goodman, MDp. Sertraline vs. placebo for Major Depression After Myocardial Infarction: the SADHART Trial (Pfizer). PI: WKGoodman, MDq. Olanzapine vs. Haloperidol in First-episode Psychotic Disorders (Lilly). PI: WK Goodman, MDr. Reboxetine in the Treatment of Major Depressive Disorders (Pharmacia & Upjohn). PI: WK Goodman, MDs. 15555U88 vs. placebo in the Treatment Of Attention Deficit/Hyperactivity Disorder (GlaxoWellcome). PI: WKGoodman, MDt. Fluoxetine vs. placebo in PTSD (Eli Lilly). PI: WK Goodman, MDu. Efficacy and Safety of Mecamylamine in the Treatment of Tourette Disorder (Layton Bioscience). PI: WKGoodman, MDv. Paroxetine vs. placebo in Patients with GAD (SmithKline Beecham). PI: WK Goodman, MDw. Fluvoxamine CR vs. placebo in outpatient with OCD (Solvay Pharmaceuticals). PI: WK Goodman, MDx. Topiramate vs. placebo in the Treatment of Acute Manic or Mixed Episodes in Subjects with Bipolar I Disorder(RW Johnson). PI: WK Goodman, MDy. Olanzapine vs. Placebo in the Prevention of Relapse in Bipolar Disorder (Eli Lilly). PI: WK Goodman, MDz. Flexible Dose Comparison of the Safety and Efficacy of S-citalopram, Racemic Citalopram and Placebo in theTreatment of Major Depressive Disorder (Forest Laboratories). PI: WK Goodman, MDaa. The Combination of Olanzapine and Fluoxetine in Treatment Resistant Depression without Psychotic Features(Eli Lilly). PI: WK Goodman, MDbb. A Placebo-Controlled Study Of The Efficacy And Tolerability Of Paroxetine In The Treatment Of ChildrenAnd Adolescents With Social Anxiety Disorder/Social Phobia (SmithKline Beecham). PI: Miguel Mandoki,Updated 12/12/2009

MD; Co-PI: WK Goodman, MD.cc. A Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Paroxetine In Children And AdolescentsWith Obsessive-Compulsive Disorder. (SmithKline Beecham). PI: Tanya K. Murphy, MD; Co-PI: WKGoodman, MD.dd. Flexible Dose Comparison of the Safety and Efficacy of Lu 26-054 and Placebo in the Treatment ofGeneralized Anxiety Disorder (Forest Laboratories). PI: WK Goodman, MDee. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Citalopram inChildren and Adolescents with Depression (Forest Laboratories). PI: WK Goodman, MDff. Double-blind, randomized, parallel-group, active-and placebo-controlled study to evaluate safety and efficacyof an investigational medication in patients with Social Phobia (Novartis). PI: WK Goodman, MDgg. Evaluation of the Safety and Efficacy of Lu 26-054 in the Prevention of Depression Recurrence (ForestLaboratories). PI: WK Goodman, MDhh. Fixed Dose Continuation Study of Escitalopram in the Treatment of Depressed Nonresponders (ForestLaboratories). PI: WK Goodman, MDii. Placebo-Controlled Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients withGeneralized Anxiety Disorder (GlaxoSmithKline). PI: WK Goodman, MDjj. Study Evaluating the Efficacy and Safety of SB-29060 controlled release vs. Placebo in Patients with MajorDepressive Disorder (GlaxoSmithKline). PI: WK Goodman, MDkk. Placebo-Controlled 3-Month Clinical Trial of Venlafaxine ER and Sertraline in the Treatment of PTSD (Wyeth-Ayerst). PI: WK Goodman, MDll. Phase II, Twelve Week, Double Blind and Placebo Controlled Study to Evaluate the Safety and Efficacy ofTwo Doses of CP 448,187 in Subjects with OCD (Pfizer). PI: WK Goodman, MDmm. A Randomized, Double-Blind, Placebo Controlled Trial of Escitalopram in Pathological Gamblers (ForestLaboratories). PI: WK Goodman, MD (Investigator-initiated).4. Private and Institutional Grants:a. Double-Blind Crossover Study of Risperidone vs. Placebo in Tourette's Syndrome Patients with or withoutAssociated Tics. University of Florida DSR New Faculty Support Program. PI: WK Goodman, MDb. Longitudinal Course of Obsessive Compulsive Disorder in College Students. University of Florida DSR NewFaculty Support Program. PI: Marcia Morris, MD; Co-Investigator: WK Goodman, MDc. Risperidone in the treatment of Tourette’s syndrome. Tourette Syndrome Association. PI: WK Goodman, MDd. Frequency of D8/17 Antistreptococcal & Antineuronal Antibodies in Patients with Childhood-onset OCDand/or TS. University of Florida DSR New Faculty Support Program. PI: Tanya K. Murphy, MD; Co-Investigator: WK Goodman, MDUpdated 12/12/2009